0001213900-26-119910 | 10-Q | XBRL Viewer

Print Document

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025
Statement [Line Items]
Stock issuance costs			$ 30	$ 319
Pre-funded warrants issuance cost	$ 230		61	$ 230
Common stock warrants issuance cost			136
Common stock to related parties issuance costs			30
Common stock warrants to related parties issuance cost			$ 45
Common stock for warrant inducement issuance cost		$ 289
Series C Common Stock Warrants
Statement [Line Items]
Common stock warrants issuance cost	217
Series D Common Stock Warrants
Statement [Line Items]
Common stock warrants issuance cost	$ 205
At-The-Market
Statement [Line Items]
Stock issuance costs					$ 84

Balance Sheet Components

9 Months Ended

Sep. 30, 2026

Balance Sheet Components [Abstract]

BALANCE SHEET COMPONENTS

4. BALANCE SHEET COMPONENTS

Prepaid expenses and other current assets consist of the following:

	September 30, 2026		December 31, 2025
Prepaid expenses	$	295	$	207
Other current assets		417		355
Total	$	712	$	562

Property and equipment, net, consists of the following:

	September 30, 2026			December 31, 2025
Computer equipment and software	$	151		$	151
Furniture and fixtures		263			263
Lab equipment		1,446			1,446
Leasehold improvements		198			198
Property and equipment		2,058			2,058
Less accumulated depreciation		(1,629	)		(1,453	)
Property and equipment—net	$	429		$	605

Depreciation expense for the three and nine months ended September 30, 2026 was $57 and $176, respectively. Depreciation expense for the three and nine months ended September 30, 2025 was $66 and $201, respectively.

Accrued liabilities consist of the following:

	September 30, 2026		December 31, 2025
Consulting, accounting & legal fees	$	717	$	447
Contract research & lab equipment		154		7
Board fees and taxes		19		150
Other		37		23
Accrued clinical trial liability		53		310
Total	$	980	$	937

Stock-Based Compensation - Schedule of Summary of Grant Date Fair Value (Details) - Share-based Payment Arrangement, Employee [Member]	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Schedule of Summary of Grant Date Fair Value [Line Items]
Expected term (in years)	6 years 1 month 6 days	6 years
Risk-free interest rate	4.00%	4.40%
Dividends
Minimum [Member]
Schedule of Summary of Grant Date Fair Value [Line Items]
Expected volatility, Minimum	135.00%	115.00%
Maximum [Member]
Schedule of Summary of Grant Date Fair Value [Line Items]
Expected volatility, maximum	152.00%	116.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Stockholders' Equity (Deficit)	9 Months Ended
Sep. 30, 2026
Stockholders' Equity (Deficit) [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	7. STOCKHOLDERS’ EQUITY (DEFICIT) Authorized Stock The Company is authorized to issue 100,000,000 shares of common stock, par value of $0.001 per share, and 5,000,000 shares of preferred stock, 100,000 of which have been designated as Series A Participating Preferred Stock (the “Series A Preferred Stock”), par value of $0.001 per share pursuant to the Company’s Rights Plan (as defined below). No shares of the Company’s Series A Participating Preferred Stock were outstanding as of September 30, 2026 and 2025. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no cash dividends declared to date. The holders of each share of common stock are entitled to one vote. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders. Rights Plan On October 10, 2023, the Company’s Board of Directors adopted a limited duration stockholder rights plan (the “Rights Plan”), effective immediately, and declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock. The dividend was effective as of October 23, 2023 (the “Record Date”) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of the Series A Preferred Stock at a price of $25.00 per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement”), between the Company and Computershare Trust Company, NA. On October 9, 2024, the Company entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company’s 2025 Annual Meeting of Stockholders or, if the Company’s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company. On December 5, 2024, the Company entered into Amendment No. 2 (the “Second Amendment”) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company’s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. On January 27, 2026, the Company’s stockholders approved the Company’s Rights Agreement. Such stockholder approval extended the final expiration date of the Rights Agreement until October 10, 2026. The Rights Agreement expired in accordance with its terms on October 10, 2026, and the Rights are no longer outstanding. Equity Line of Credit On August 13, 2026, the Company entered into the Lincoln Park Purchase Agreement and a registration rights agreement with Lincoln Park. Under the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25.0 million of its common stock, increasing to $50.0 million if the initial $25.0 million is sold, from time to time over a 24-month period beginning September 1, 2026. Shares are sold at a discount to market prices and subject to certain limitations, including a minimum price of $0.15 per share, pricing formulas, volume caps, the effectiveness of a registration statement registering the resale by Lincoln Park of shares of common stock sold, a limit of 3,195,881 shares (19.99% of the shares outstanding at signing) unless stockholder approval is obtained or the average sale price equals or exceeds $1.3854 per share, and a limit of 4.99% on Lincoln Park’s beneficial ownership. On November 9, 2026, the Company obtained stockholder approval to issue shares above the limit of 3,195,881 shares. The Company may terminate the Lincoln Park Purchase Agreement at any time without cost. As consideration for Lincoln Park’s commitment, the Company issued 560,356 shares of common stock to Lincoln Park upon signing and agreed to issue an additional 350,223 shares following full funding by Lincoln Park of the initial available amount of $25.0 million of common stock. Because certain settlement provisions are not indexed to the Company’s own stock, the Lincoln Park Purchase Agreement is accounted for as a derivative liability measured at fair value, with changes recognized in the condensed consolidated statements of operations. Its fair value was de minimis at inception and as of September 30, 2026. The 560,356 shares issued at signing had a fair value of $0.66 million and, together with $0.15 million of issuance costs, were expensed as financing costs related to the equity line of credit within other income (expense). During the three and nine months ended September 30, 2026, the Company sold 350,000 shares of common stock to Lincoln Park for gross proceeds of $0.3 million. The difference between the discounted purchase price and the fair value of shares sold was nominal. September 2026 Private Placement On September 11, 2026, the Company entered into the September 2026 Purchase Agreement with an institutional investor for the sale, in a private placement that closed on September 15, 2026, of the September Pre-Funded Warrants to purchase 3,105,591 shares of common stock, accompanied by Series C Warrants and Series D Warrants, each to purchase 3,105,591 shares of common stock. The combined purchase price was $0.804 per pre-funded warrant and accompanying September Common Warrants, for gross proceeds of approximately $2.5 million. Cash issuance costs of approximately $0.65 million were recorded as a reduction of additional paid-in capital. The September 2026 Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and do not expire. The September Common Warrants have an exercise price of $0.805 per share and become exercisable upon stockholder approval of the issuance of the underlying shares under Nasdaq rules (the “Stockholder Approval Date”), which the Company is required to seek within 90 days of signing and every 90 days thereafter until obtained. On November 9, 2026, the Company obtained stockholder approval for the issuance of the shares of common stock underlying the September Common Warrants. The Series C Warrants expire six years, and the Series D Warrants three years, after the Stockholder Approval Date. Exercise is limited to 9.99% beneficial ownership for the pre-funded warrants and 4.99% (or 9.99% at the holder’s election) for the September Common Warrants. All September Pre-Funded Warrants were subsequently exercised in October 2026. Upon a fundamental transaction within the Company’s control, holders of the September Common Warrants may require the Company to purchase the unexercised portion for cash at its Black-Scholes value. The Company also issued warrants to purchase 217,391 shares of common stock at $1.0063 per share to the placement agent on substantially the same terms as the Series C Warrants, recorded at their grant-date fair value of $0.15 million as an equity issuance cost and a corresponding increase to additional paid-in capital, with no net effect on total stockholders’ equity (deficit). The September 2026 Pre-Funded Warrants and the September Common Warrants are classified in stockholders’ equity and are not subsequently remeasured. Gross proceeds were allocated to the instruments based on their relative fair values, determined using the Black-Scholes option pricing model: $0.9 million to the pre-funded warrants, $0.8 million to the Series C Warrants and $0.8 million to the Series D Warrants, recorded in additional paid-in capital. In connection with the September 2026 Private Placement, the Company entered into a registration rights agreement requiring it to file a resale registration statement within 15 days, have it declared effective within 45 days (75 days if reviewed by the SEC) and maintain its effectiveness. If the Company fails to do so, it must pay the investor cash liquidated damages of 1.0% per month of the affected purchase price, up to a maximum of 6.0% (approximately $0.15 million). The registration statement was filed on September 25, 2026 and declared effective on October 1, 2026. No liquidated damages have been incurred, and no liability was recorded as of September 30, 2026.

Stockholders' Equity (Deficit)

9 Months Ended

Sep. 30, 2026

Stockholders' Equity (Deficit) [Abstract]

STOCKHOLDERS’ EQUITY (DEFICIT)

7. STOCKHOLDERS’ EQUITY (DEFICIT)

Authorized Stock

The Company is authorized to issue 100,000,000 shares of common stock, par value of $0.001 per share, and 5,000,000 shares of preferred stock, 100,000 of which have been designated as Series A Participating Preferred Stock (the “Series A Preferred Stock”), par value of $0.001 per share pursuant to the Company’s Rights Plan (as defined below). No shares of the Company’s Series A Participating Preferred Stock were outstanding as of September 30, 2026 and 2025. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no cash dividends declared to date. The holders of each share of common stock are entitled to one vote. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders.

Rights Plan

On October 10, 2023, the Company’s Board of Directors adopted a limited duration stockholder rights plan (the “Rights Plan”), effective immediately, and declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock. The dividend was effective as of October 23, 2023 (the “Record Date”) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of the Series A Preferred Stock at a price of $25.00 per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement”), between the Company and Computershare Trust Company, NA.

On October 9, 2024, the Company entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company’s 2025 Annual Meeting of Stockholders or, if the Company’s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company.

On December 5, 2024, the Company entered into Amendment No. 2 (the “Second Amendment”) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company’s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder.

On January 27, 2026, the Company’s stockholders approved the Company’s Rights Agreement. Such stockholder approval extended the final expiration date of the Rights Agreement until October 10, 2026. The Rights Agreement expired in accordance with its terms on October 10, 2026, and the Rights are no longer outstanding.

Equity Line of Credit

On August 13, 2026, the Company entered into the Lincoln Park Purchase Agreement and a registration rights agreement with Lincoln Park. Under the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25.0 million of its common stock, increasing to $50.0 million if the initial $25.0 million is sold, from time to time over a 24-month period beginning September 1, 2026. Shares are sold at a discount to market prices and subject to certain limitations, including a minimum price of $0.15 per share, pricing formulas, volume caps, the effectiveness of a registration statement registering the resale by Lincoln Park of shares of common stock sold, a limit of 3,195,881 shares (19.99% of the shares outstanding at signing) unless stockholder approval is obtained or the average sale price equals or exceeds $1.3854 per share, and a limit of 4.99% on Lincoln Park’s beneficial ownership. On November 9, 2026, the Company obtained stockholder approval to issue shares above the limit of 3,195,881 shares. The Company may terminate the Lincoln Park Purchase Agreement at any time without cost.

As consideration for Lincoln Park’s commitment, the Company issued 560,356 shares of common stock to Lincoln Park upon signing and agreed to issue an additional 350,223 shares following full funding by Lincoln Park of the initial available amount of $25.0 million of common stock. Because certain settlement provisions are not indexed to the Company’s own stock, the Lincoln Park Purchase Agreement is accounted for as a derivative liability measured at fair value, with changes recognized in the condensed consolidated statements of operations. Its fair value was de minimis at inception and as of September 30, 2026. The 560,356 shares issued at signing had a fair value of $0.66 million and, together with $0.15 million of issuance costs, were expensed as financing costs related to the equity line of credit within other income (expense). During the three and nine months ended September 30, 2026, the Company sold 350,000 shares of common stock to Lincoln Park for gross proceeds of $0.3 million. The difference between the discounted purchase price and the fair value of shares sold was nominal.

September 2026 Private Placement

On September 11, 2026, the Company entered into the September 2026 Purchase Agreement with an institutional investor for the sale, in a private placement that closed on September 15, 2026, of the September Pre-Funded Warrants to purchase 3,105,591 shares of common stock, accompanied by Series C Warrants and Series D Warrants, each to purchase 3,105,591 shares of common stock. The combined purchase price was $0.804 per pre-funded warrant and accompanying September Common Warrants, for gross proceeds of approximately $2.5 million. Cash issuance costs of approximately $0.65 million were recorded as a reduction of additional paid-in capital.

The September 2026 Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and do not expire. The September Common Warrants have an exercise price of $0.805 per share and become exercisable upon stockholder approval of the issuance of the underlying shares under Nasdaq rules (the “Stockholder Approval Date”), which the Company is required to seek within 90 days of signing and every 90 days thereafter until obtained. On November 9, 2026, the Company obtained stockholder approval for the issuance of the shares of common stock underlying the September Common Warrants. The Series C Warrants expire six years, and the Series D Warrants three years, after the Stockholder Approval Date. Exercise is limited to 9.99% beneficial ownership for the pre-funded warrants and 4.99% (or 9.99% at the holder’s election) for the September Common Warrants. All September Pre-Funded Warrants were subsequently exercised in October 2026. Upon a fundamental transaction within the Company’s control, holders of the September Common Warrants may require the Company to purchase the unexercised portion for cash at its Black-Scholes value.

The Company also issued warrants to purchase 217,391 shares of common stock at $1.0063 per share to the placement agent on substantially the same terms as the Series C Warrants, recorded at their grant-date fair value of $0.15 million as an equity issuance cost and a corresponding increase to additional paid-in capital, with no net effect on total stockholders’ equity (deficit).

The September 2026 Pre-Funded Warrants and the September Common Warrants are classified in stockholders’ equity and are not subsequently remeasured. Gross proceeds were allocated to the instruments based on their relative fair values, determined using the Black-Scholes option pricing model: $0.9 million to the pre-funded warrants, $0.8 million to the Series C Warrants and $0.8 million to the Series D Warrants, recorded in additional paid-in capital.

In connection with the September 2026 Private Placement, the Company entered into a registration rights agreement requiring it to file a resale registration statement within 15 days, have it declared effective within 45 days (75 days if reviewed by the SEC) and maintain its effectiveness. If the Company fails to do so, it must pay the investor cash liquidated damages of 1.0% per month of the affected purchase price, up to a maximum of 6.0% (approximately $0.15 million). The registration statement was filed on September 25, 2026 and declared effective on October 1, 2026. No liquidated damages have been incurred, and no liability was recorded as of September 30, 2026.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Stock-Based Compensation

9 Months Ended

Sep. 30, 2026

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

8. STOCK-BASED COMPENSATION

Equity Plans

In 2011, Private Tempest adopted the 2011 Equity Incentive Plan (the “2011 Plan), and in 2017, Private Tempest adopted the 2017 Equity Incentive Plan (the “2017 Plan”), and together with the 2011 Plan, the “Tempest Prior Plans.” The Tempest Prior Plans have been terminated and no additional grants may be made under either plan. All stock awards granted under the Tempest Prior Plans will remain subject to the terms of the applicable prior plan. As a result of the merger with Millendo, the Tempest Prior Plans were assumed by the Company.

On April 29, 2019, the Board of Millendo adopted the 2019 Equity Incentive Plan (the “2019 Plan”), subject to approval by the Company’s stockholders, and became effective with such stockholder approval on June 11, 2019. On June 17, 2022, the Company’s stockholders approved the Amended and Restated 2019 Equity Incentive Plan (the “A&R 2019 Plan”), which amended and restated the 2019 Plan and was the successor to, and replacement of, the 2019 Plan.

The Board of Tempest adopted the Amended and Restated 2023 Equity Incentive Plan (the “2023 Plan”) on April 30, 2023, subject to approval by the Company’s stockholders. On June 15, 2023, the Company’s stockholders approved the 2023 Plan, which amended and restated the A&R 2019 Plan and will be a successor to, and replacement of, the A&R 2019 Plan. The number of shares of the Company’s common stock reserved for issuance under the 2023 Plan will automatically increase on January 1st of each year, for a period of 10 years, from January 1, 2024 continuing through January 1, 2033, by 4% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Accordingly, on January 1, 2026, the common stock reserved for issuance was increased by 197,086 shares. As of September 30, 2026, there were 1,468,044 shares available for future grant under the 2023 Plan. In addition, on January 27, 2026, the Company’s stockholders approved the amendment to increase the number of shares issuable under the 2023 Plan by 1,410,000 shares of common stock.

The 2023 Plan allows the Company to grant stock awards to employees, directors and consultants of the Company, including incentive stock options (“ISOs”), non-qualified stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards.

The Board of Tempest adopted the 2023 Inducement Plan (“2023 Inducement Plan”) on June 21, 2023, pursuant to which the Company reserved 88,461 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company’s Board of Directors without stockholder approval in accordance with such rule. As of September 30, 2026, there were 67,615 shares available for future grant under the 2023 Inducement Plan.

The Company measures employee and non-employee stock-based awards at grant date fair value and records compensation expense on a straight-line basis over the vesting period of the award.

Employee Stock Ownership Plan

The Millendo Board adopted the 2019 Employee Stock Purchase Plan on April 29, 2019, which became effective upon stockholder approval on June 11, 2019. On June 17, 2022, the Company’s stockholders approved the Amended and Restated 2019 Employee Stock Purchase Plan (the “2019 ESPP”). The 2019 ESPP enables employees to purchase shares of the Company’s common stock through offerings of rights to purchase the Company’s common stock to all eligible employees.

The 2019 ESPP provides that the number of shares of common stock reserved for issuance under the 2019 ESPP will automatically increase on January 1, 2023 and continuing through (and including) January 1, 2029, by the lesser of 1.5% of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year, (ii) 38,461 shares of Common Stock, or (iii) such lesser number of shares of Common Stock as determined by the Board of Directors (which may be zero). On January 1, 2026, the common stock reserved for issuance was increased by 38,461 shares.

As of September 30, 2026, 107,069 shares of common stock remained available for future issuance under the 2019 ESPP. During the three and nine months ended September 30, 2026, no shares of common stock were issued under the 2019 ESPP.

Stock Options

Options to purchase the Company’s common stock may be granted at a price not less than the fair market value in the case of both NSOs and ISOs, except for an options holder who owns more than 10% of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than 110% of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over four years and expire no later than ten (10) years from the date of grant. Vested options can be exercised at any time.

The following shows the stock option activities for the nine months ended September 30, 2026 and 2025:

	Total Options Outstanding			Weighted-Average Exercise Price
Balance—December 31, 2025		450,104		$	64.44
Granted		522,541			2.03
Exercised		—			—
Cancelled and forfeited		(405,879	)		40.17
Balance—September 30, 2026		566,766		$	23.91

Balance—December 31, 2024		320,013		$	86.06
Granted		130,091			11.20
Exercised		—			—
Cancelled and forfeited		—			—
Balance—September 30, 2025		450,104		$	64.44

The following table summarizes information about stock options outstanding at September 30, 2026:

	Shares		Weighted Average Remaining Contractual Life (In Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value
Options outstanding		566,766		5.98	$	23.91	$	—
Vested and expected to vest		566,766		5.98	$	23.91	$	—
Exercisable		221,999		0.60	$	57.68	$	—

During the nine months ended September 30, 2026 and 2025, the Company granted employees and non-employees stock options to purchase 522,541 and 130,091 shares of common stock, respectively, with a weighted-average grant date fair value of $1.81 and $11.20 per share, respectively. As of September 30, 2026 and 2025, total unrecognized compensation costs related to unvested employee stock options were $585 and $450, respectively. These costs are expected to be recognized over a weighted-average period of approximately 3.1 years and 1.7 years, respectively. The fair value of stock options vested was $0.0 million and $0.1 million for the three months ended September 30, 2026 and 2025, respectively, and $0.1 million and $1.6 million for the nine months ended September 30, 2026 and 2025, respectively.

The Company estimated the fair value of stock options using the Black-Scholes option pricing valuation model. The fair value of employee and non-employee stock options is being amortized on the straight-line basis over the requisite service period of the awards. The fair value of employee and non-employee stock options was estimated using the following assumptions for the nine months ended September 30, 2026 and 2025:

	2026			2025
Expected term (in years)		6.1			6.0
Expected volatility	135%-152		%	115%-116		%
Risk-free interest rate		4.0	%		4.4	%
Dividends		—	%		—	%

Expected Term—The expected term of options granted represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected term of the Company’s employee stock options has been determined utilizing the simplified method for awards that qualify as plain-vanilla options.

Expected Volatility—The expected stock price volatility assumption was determined by examining the historical volatility of the Company’s common stock and the historical volatilities of a group of industry peers. For grants made during the three months ended March 31, 2026, the Company weighted its own historical volatility and peer volatility 25% and 75%, respectively. For grants made during the three months ended September 30, 2026, the Company weighted these inputs 50% and 50%, respectively. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company’s common stock becomes available.

Risk-Free Interest Rate—The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options.

Dividends—The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used.

During the year ended December 31, 2025, the Company accelerated the vesting of approximately 266,108 time-based vesting stock options grants previously awarded to the Company’s employees, pursuant to the separation agreements entered into with such employees. The Company also extended the post-termination exercise period from 90 days to 180 days immediately following the separation date for any options that were vested, including the options that were accelerated in vesting, as described above. Further, in the fourth quarter of 2025, approximately 416,005 of modified stock options were further modified to extend the post-termination exercise period from either (i) 180 days to December 31, 2026 or (ii) to the earlier of (a) the date that is 90 days following termination of continuous service, and (b) the expiration of the term of the options as set forth in the award agreements.

The above modifications to current and former employees stock options grants resulted in modification accounting under ASC 718, Compensation – Stock Compensation. As a result, the Company recognized approximately $0.1 million of stock compensation expense during the three months ended March 31, 2026 and $0.8 million of stock compensation expense during the year ended December 31, 2025. For vested awards with no future service period required to be provided, the expense was measured on the modification date by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified with immediate expense recognition. For unvested awards with no future service period required to be provided, the Company reversed any stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized stock compensation expense on the modification date. For stock options that were further modified to extend the post-termination exercise period upon termination of continuous service, the Company measured the expense by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The fair value of those awards included a reduction to the share price for the fair value of the warrant dividend as the holders of the modified stock options were not participants in the warrant dividend. For certain awards held by two of the Company’s former executive officers that were deemed to be deeply out-of-the-money, the modification established a derived service period. A portion of the related incremental compensation cost was recorded as stock-based compensation expense in the fourth quarter of 2025, with the remainder initially attributed over the derived service period.

During the nine months ended September 30, 2026, the Company’s former President and Chief Executive Officer and former Chief Financial Officer and Head of Corporate Strategy separated from the Company. The former President and Chief Executive Officer stepped down from his executive position on February 3, 2026 but continued to provide service to the Company as a member of the Board of Directors until his resignation from the Board on May 22, 2026. The former Chief Financial Officer and Head of Corporate Strategy separated from the Company on June 5, 2026. Because the derived service period associated with their out-of-the-money modified awards was not completed as of their respective separation dates, the previously recognized incremental compensation cost related to those awards was reversed during the three months ended June 30, 2026, and no further incremental compensation cost will be recognized. The reversal totaled approximately $0.2 million and reduced stock-based compensation expense within general and administrative expense for the nine months ended September 30, 2026.

Stock-Based Compensation Expense

The following table summarizes the components of stock-based compensation expense recognized in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2026 and 2025:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Research and development	$	3	$	9	$	8	$	979
General and administrative		51		52		155		1,563
Total	$	54	$	61	$	163	$	2,542

Stock-Based Compensation - Schedule of Summary of Information About Stock Options Outstanding (Details) - USD ($)	9 Months Ended
	Sep. 30, 2026	Dec. 31, 2025	Jun. 30, 2025	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	566,766	450,104	450,104	320,013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 11 months 23 days
Outstanding (in dollars per share)	$ 23.91	$ 64.44	$ 64.44	$ 86.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	566,766
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	5 years 11 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 23.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	221,999
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 57.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2026	Nov. 13, 2026
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2026
Document Transition Report	false
Entity File Number	001-35890
Entity Registrant Name	Tempest Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-1472564
Entity Address, Address Line One	2000 Sierra Point Parkway
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	(415)
Local Phone Number	798-8589
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,995,358
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2026
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001544227
Common Stock, $0.001 par value
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	TPST
Security Exchange Name	NASDAQ
Series A Junior Participating Preferred Purchase Rights
Document Information [Line Items]
Title of 12(b) Security	Series A Junior Participating Preferred Purchase Rights
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ

Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Numerator:
Net loss	$ (3,629)	$ (5,244)	$ (27,696)	$ (3,511)	$ (7,870)	$ (10,860)	$ (36,569)	$ (22,241)
Denominator:
Weighted-average common shares outstanding	16,910,029			4,440,111			14,377,097	3,897,256
Weighted-average shares used in computing basic net loss per share	16,910,029			4,440,111			14,377,097	3,897,256
Weighted-average shares used in computing diluted net loss per share	16,910,029			4,440,111			14,377,097	3,897,256
Net loss per share attributable to common stockholders - basic	$ (0.21)			$ (0.79)			$ (2.54)	$ (5.71)
Net loss per share attributable to common stockholders - diluted	$ (0.21)			$ (0.79)			$ (2.54)	$ (5.71)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Organization and Description of the Business (Details) $ / shares in Units, $ in Thousands															1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 22, 2026 USD ($)	Sep. 11, 2026 USD ($) shares	Aug. 13, 2026 USD ($) $ / shares	May 29, 2026 USD ($)	May 28, 2026 USD ($) $ / shares shares	May 12, 2026 USD ($)	Mar. 20, 2026 USD ($) $ / shares shares	Feb. 03, 2026 USD ($) $ / shares shares	Jan. 20, 2026 $ / shares	Nov. 24, 2025 USD ($) $ / shares shares	Nov. 19, 2025 shares	Jun. 05, 2025 USD ($)	Jun. 20, 2024 USD ($)	Jul. 23, 2021 USD ($)	Jun. 30, 2026 shares	Apr. 30, 2026 USD ($)	Mar. 31, 2026 USD ($) shares	Apr. 30, 2025 Employees	Sep. 30, 2026 USD ($) $ / shares	Mar. 31, 2026 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Jun. 18, 2026 $ / shares	Feb. 06, 2025 USD ($)
Organization and Description of the Business [Line Items]
Number of employees eliminated \| Employees																		21
Number of full time employees \| Employees																		26
Effective date of workforce reduction																		Apr. 30, 2025
Cash and cash equivalents																			$ 897				$ 897		$ 7,707
Cash one-time severance payments												$ 3,200
Research and development expense																			100
General and administrative expense																			$ 2,616		$ 3,027		$ 11,473	$ 10,431
Exercise price \| $ / shares									$ 18.48										$ 0.805				$ 0.805
Warrants issued \| shares								6,784,989
Aggregate sales price of common stock																				$ 170		$ 3,570
Gross proceeds																							$ 300
Stock price (in dollars per share) \| $ / shares																			$ 0.15				$ 0.15
Waiver amount payable under Factor MSA						$ 2,100
Issuance costs																			$ 150				$ 150
Owing percentage			4.99%
Waiver payment value																							$ 400
Series C Warrants [Member]
Organization and Description of the Business [Line Items]
Purchase of warrants \| shares		3,105,591
Series D Warrants [Member]
Organization and Description of the Business [Line Items]
Purchase of warrants \| shares		3,105,591
Pre-Funded Warrant [Member]
Organization and Description of the Business [Line Items]
Purchase of warrants \| shares		3,105,591
Common Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares							$ 2.159
Warrant Dividend [Member]
Organization and Description of the Business [Line Items]
Dividend record date									Jan. 30, 2026
Erigen Assets [Member]
Organization and Description of the Business [Line Items]
Asset acquisition, stock issued as consideration \| shares								8,268,495
Asset acquisition, stock price per share \| $ / shares								$ 2.41
Transaction costs								$ 2,253
At-The-Market Program [Member]
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares
Remained available for issuance of common stock																											$ 14,500
Private Placement [Member]
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares																	231,482
Private Placement [Member] \| Warrants [Member]
Organization and Description of the Business [Line Items]
Warrants and rights outstanding																	$ 500			500
Registered Direct Offering and Warrant Inducement [Member]
Organization and Description of the Business [Line Items]
Consideration received										$ 3,800
Registered Direct Offering and Warrant Inducement [Member] \| November 2025 Pre Funded Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares										$ 0.001
Number of warrants issued \| shares										685,414
Stock price (in dollars per share) \| $ / shares										$ 3.624
Registered Direct Offering and Warrant Inducement [Member] \| May 2026 Inducement Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares					$ 1.73
Registered Direct Offering and Warrant Inducement [Member] \| November 2025 Common Warrants [Member]
Organization and Description of the Business [Line Items]
Consideration received					$ 2,000
Exercise price \| $ / shares					$ 1.73
Fair value of warrants				$ 2,000
Warrants and rights outstanding					$ 2,400
Registered Direct Offering and Warrant Inducement [Member] \| Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares					$ 3.5					$ 3.5
Warrants and rights outstanding					$ 400
Number of warrants issued \| shares										1,172,414
Registered Direct Offering and Warrant Inducement [Member] \| Unregistered Warrant [Member]
Organization and Description of the Business [Line Items]
Warrants issued \| shares					2,344,828
Common Stock, $0.001 par value
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares																							8,000,000
Aggregate sales price of common stock
Common Stock, $0.001 par value \| Registered Direct Offering and Warrant Inducement [Member]
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares										487,000
Stock price (in dollars per share) \| $ / shares										$ 3.625
Maximum [Member]
Organization and Description of the Business [Line Items]
Gross proceeds																							$ 4,000
Public float																							75,000
Issuance costs			$ 50,000
Sale of securities		$ 5,000
Minimum [Member]
Organization and Description of the Business [Line Items]
Gross proceeds																							2,000
Issuance costs			$ 25,000
Sale of securities		$ 2,500
Asset Purchase Agreement [Member]
Organization and Description of the Business [Line Items]
Asset acquisition, maximum funding commitment								20,000
Asset acquisition availability remained under funding commitment																			8,900				8,900
Asset Purchase Agreement [Member] \| Erigen Assets [Member]
Organization and Description of the Business [Line Items]
Cash one-time severance payments								$ 1,500
Asset acquisition availability remained under funding commitment																			$ 8,900				8,900
Asset acquisition, agreement date											Nov. 19, 2025
Asset acquisition, effective date								Feb. 03, 2026
Asset acquisition, equity issued								$ 19,900
Transaction costs								$ 2,200
Research and development expense																				$ 22,100
General and administrative expense																									$ 2,200
Exercise price \| $ / shares								$ 18.48
Fair value of warrants								$ 9,000
Asset Purchase Agreement [Member] \| Common Stock, $0.001 par value \| Erigen Assets [Member]
Organization and Description of the Business [Line Items]
Asset acquisition, stock to be issued \| shares											8,268,495
Asset acquisition, stock issued as consideration \| shares								8,268,495
Asset acquisition, stock price per share \| $ / shares								$ 2.41
Letter Agreement [Member]
Organization and Description of the Business [Line Items]
Waiver amount payable under Factor MSA						2,100
Reversal of factor deposit						$ 200
Warrant Exercise and Inducement Letter Agreement [Member] \| Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares					$ 1.73
Number of warrants issued \| shares					1,172,414
Warrant Exercise and Inducement Letter Agreement [Member] \| Placement Agent [Member] \| Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares					$ 2.1625
Number of warrants issued \| shares					82,069
Aggregate sales price of common stock					$ 100
Registration Rights Agreement [Member] \| Common Stock, $0.001 par value
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares															2,426,897
Factor Master Service Agreement [Member]
Organization and Description of the Business [Line Items]
Factor deposit paid																$ 400
Work Order No. 1 [Member]
Organization and Description of the Business [Line Items]
Research and development expense																							$ 1,700
Senlang Collaboration [Member]
Organization and Description of the Business [Line Items]
Project management fee percentage	10.00%
Fixed fee	$ 5,000
Purchase Agreement [Member] \| Series A Warrants [Member]
Organization and Description of the Business [Line Items]
Number of warrants issued \| shares							925,927
Purchase Agreement [Member] \| Series B Warrants [Member]
Organization and Description of the Business [Line Items]
Number of warrants issued \| shares							925,927
Purchase Agreement [Member] \| Pre Funded Warrant And Common Warrants [Member]
Organization and Description of the Business [Line Items]
Shares Issued, Price Per Share \| $ / shares							$ 0.804
Purchase Agreement [Member] \| Pre-Funded Warrant [Member]
Organization and Description of the Business [Line Items]
Number of warrants issued \| shares							462,963
Shares Issued, Price Per Share \| $ / shares							$ 2.16
Purchase Agreement [Member] \| Common Warrants [Member]
Organization and Description of the Business [Line Items]
Consideration received							$ 5,000
Purchase Agreement [Member] \| Private Placement [Member]
Organization and Description of the Business [Line Items]
Consideration received							$ 2,500
Shares issued in transaction \| shares							462,964
Purchase Agreement [Member] \| Private Placement [Member] \| Series A Warrants [Member]
Organization and Description of the Business [Line Items]
Exercise price \| $ / shares																										$ 2.16
Purchase Agreement [Member] \| Maximum [Member] \| Common Warrants [Member]
Organization and Description of the Business [Line Items]
Consideration received					4,200		$ 4,000
Purchase Agreement [Member] \| Minimum [Member] \| Private Placement [Member]
Organization and Description of the Business [Line Items]
Consideration received					$ 2,000		$ 2,000
Jefferies LLC [Member] \| At-The-Market Program [Member]
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares																							9,017,110
Gross proceeds													$ 42,700
Net proceeds from sales of common stock													41,500
Jefferies LLC [Member] \| Maximum [Member] \| At-The-Market Program [Member]
Organization and Description of the Business [Line Items]
Aggregate sales price of common stock													$ 205,000	$ 100,000
Percentage of commission on sale of stock														3.00%
Lincoln Park [Member]
Organization and Description of the Business [Line Items]
Shares issued in transaction \| shares																							350,000
Gross proceeds																							$ 300
Stock price (in dollars per share) \| $ / shares			$ 0.15
Issuance costs			$ 25,000
ELOC [Member]
Organization and Description of the Business [Line Items]
Issuance costs			$ 50,000
ATM Program [Member] \| Maximum [Member]
Organization and Description of the Business [Line Items]
Public float																							10,200
ATM Program [Member] \| Minimum [Member]
Organization and Description of the Business [Line Items]
Public float																							$ 3,400

Erigen Assets Acquisition and Related Transactions

9 Months Ended

Sep. 30, 2026

Erigen Assets Acquisition and Related Transactions [Abstract]

ERIGEN ASSETS ACQUISITION AND RELATED TRANSACTIONS

12. ERIGEN ASSETS ACQUISITION AND RELATED TRANSACTIONS

Erigen Assets Acquisition

On February 3, 2026, the Company completed the acquisition of the Erigen Assets under the Asset Purchase Agreement. For more information on the acquired assets, please see Note 1 under “Acquisition of Erigen Assets.” No employees or tangible operating assets were acquired from the Sellers. As consideration for the Asset Acquisition, the Company issued to Erigen 8,268,495 shares of the Company’s common stock.

The Company determined that the Erigen Assets do not meet the definition of a business under ASC 805, Business Combinations, as the Erigen Assets represent inputs without a substantive process or organized workforce. Accordingly, the Asset Acquisition was accounted for as an asset acquisition in accordance with ASC 805-50. Under ASC 805-50, transaction costs are included in the cost of an asset acquisition.

The total cost of the Asset Acquisition was calculated as follows (amounts in thousands, except share and per share amounts):

Shares issued to Erigen		8,268,495
Closing price of common stock on the acquisition date	$	2.41
Fair value of shares issued		19,927

Transaction costs		2,253
Total consideration	$	22,180

The Erigen Assets are in-process research and development assets with no alternative future use. TPST-2003 and TPST-2206 are autologous CAR-T programs that will require substantial U.S.-specific development activities, including preclinical comparability studies, IND filings, and clinical trials, before they could generate future economic benefits. TPST-3003 and TPST-3206 are discovery-stage allogeneic programs requiring significant preclinical and clinical development. As the acquired assets have no alternative future use, the cost of the Asset Acquisition was expensed to in-process research and development. Approximately $2.2 million was incurred and expensed as general and administrative expense during the year ended December 31, 2025, prior to the closing of the Asset Acquisition, with the remaining $22.1 million expensed as acquired in-process research and development during the three months ended March 31, 2026. The fair value of the shares issued was recorded as an increase to common stock (at par) and additional paid-in capital on the date of the Erigen Closing.

The Erigen Assets are subject to license and collaboration agreements with Novatim Immune Therapeutics and Factor, under which the Company may be obligated to make future contingent milestone payments upon the achievement of specified development and commercial milestones and to pay royalties on future net product sales. The contingent milestone payments do not meet the definition of a derivative under ASC 815, Derivatives and Hedging, based on applicable scope exceptions and will be recognized when the respective milestones are achieved and the consideration becomes payable. Royalty obligations will be recognized in the period in which the corresponding net product sales occur. As of September 30, 2026, no milestone or royalty payments have been recognized as no milestones have been achieved and no product sales have occurred.

Pursuant to the Asset Purchase Agreement, Factor has made a Funding Commitment. Please see Note 1 under “—Acquisition of Erigen Assets.” As of September 30, 2026, $8.9 million of availability remained under the Funding Commitment.

Warrant Dividend

In connection with the Asset Acquisition, on February 3, 2026, the Company issued warrants to purchase shares of common stock as a dividend to holders of record as of January 30, 2026. Please see Note 1 under “—Warrant Dividend.” Each warrant entitles the holder to purchase one share of common stock at an exercise price of $18.48 per share, is exercisable upon effectiveness of a registration statement covering the underlying shares, and expires on February 3, 2031. The warrants are exercisable only for cash and are subject to a 9.9% beneficial ownership limitation. The Company determined that the warrants meet the criteria for equity classification under ASC 480, Distinguishing Liabilities from Equity, and ASC 815. The fair value of the warrants on the issuance date was determined to be approximately $9.0 million using a Black-Scholes option pricing model and was recorded as a reclassification within stockholders equity (deficit) with no impact to the condensed consolidated statement of operations.

Compensation Agreements

In connection with the Asset Acquisition, the Company’s Compensation Committee approved severance payments of approximately $1.5 million and success bonuses of approximately $0.8 million to certain officers and employees. These payments were made pursuant to pre-existing employment and success bonus agreements and were recognized as compensation expense during the nine months ended September 30, 2026, separate from the acquired in-process research and development expense.

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details

Erigen Assets Acquisition and Related Transactions (Details) - Asset Purchase Agreement [Member] - Erigen Assets [Member] - USD ($) $ / shares in Units, $ in Millions		9 Months Ended	12 Months Ended
	Feb. 03, 2026	Sep. 30, 2026	Dec. 31, 2025	Mar. 31, 2026
Erigen Assets Acquisition and Related Transactions [Line Items]
Asset acquisition, effective date	Feb. 03, 2026
General and administrative expense			$ 2.2
Exercise price	$ 18.48
Fair value of warrants	$ 9.0
Percentage of beneficial ownership limitation of class of warrant exercisable only for cash	9.90%
Asset acquisition availability remained under funding commitment		$ 8.9
Severance payments	$ 1.5
Royalty payments
Deferred Bonus [Member]
Erigen Assets Acquisition and Related Transactions [Line Items]
Aggregate success bonuses	$ 0.8
O 2026 Q1 Dividends [Member]
Erigen Assets Acquisition and Related Transactions [Line Items]
Dividend record date	Jan. 30, 2026
In Process Research and Development [Member]
Erigen Assets Acquisition and Related Transactions [Line Items]
Asset acquisition expensed				$ 22.1
Common Stock, $0.001 par value
Erigen Assets Acquisition and Related Transactions [Line Items]
Asset acquisition, stock issued as consideration	8,268,495

Erigen Assets Acquisition and Related Transactions - Schedule of Total Cost of Asset Acquisition (Details) - Erigen Assets [Member] $ / shares in Units, $ in Thousands	Feb. 03, 2026 USD ($) $ / shares shares
Schedule of Total Cost of Asset Acquisition [Line Items]
Shares issued to Erigen \| shares	8,268,495
Closing price of common stock on the acquisition date \| $ / shares	$ 2.41
Fair value of shared issued \| shares	19,927
Transaction costs \| $	$ 2,253
Total consideration \| $	$ 22,180

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2026

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Lease Payments

As of September 30, 2026, future minimum lease payments under the Company’s operating lease liabilities were as follows:

Year Ending	Total Commitment
2026 (excluding nine months ended September 30, 2026)	$	482
2027		1,994
2028		2,064
2029		2,136
2030		2,210
Total minimum lease payments		8,886
Less: imputed interest		(1,628	)
Present value of operating lease obligations		7,258
Less: current portion		(1,336	)
Noncurrent operating lease obligations	$	5,922

Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2026

Balance Sheet Components [Abstract]

Schedule of Prepaid Expenses and Other Current Asset

Prepaid expenses and other current assets consist of the following:

	September 30, 2026		December 31, 2025
Prepaid expenses	$	295	$	207
Other current assets		417		355
Total	$	712	$	562

Summary of Property and Equipment, Net

Property and equipment, net, consists of the following:

	September 30, 2026			December 31, 2025
Computer equipment and software	$	151		$	151
Furniture and fixtures		263			263
Lab equipment		1,446			1,446
Leasehold improvements		198			198
Property and equipment		2,058			2,058
Less accumulated depreciation		(1,629	)		(1,453	)
Property and equipment—net	$	429		$	605

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:

	September 30, 2026		December 31, 2025
Consulting, accounting & legal fees	$	717	$	447
Contract research & lab equipment		154		7
Board fees and taxes		19		150
Other		37		23
Accrued clinical trial liability		53		310
Total	$	980	$	937

Fair Value Measurements

9 Months Ended

Sep. 30, 2026

Fair Value Measurements [Abstract]

FAIR VALUE MEASUREMENTS

3. FAIR VALUE MEASUREMENTS

The following tables present the Company’s fair value hierarchy for assets measured at fair value on a recurring basis:

	As of September 30, 2026
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	897	$	—	$	—	$	897
Total	$	897	$	—	$	—	$	897

	As of December 31, 2025
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	7,707	$	—	$	—	$	7,707
Total	$	7,707	$	—	$	—	$	7,707

The derivative liability associated with the Lincoln Park Purchase Agreement (see Notes 2 and 7) had a de minimis fair value at inception and as of September 30, 2026 and is therefore not presented in the table above.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Total

Balance at Dec. 31, 2024

$ 3

$ 226,229

$ (207,106)

$ 19,126

Balance (in Shares) at Dec. 31, 2024

^[1]

3,382,432

Statement [Line Items]

Issuance of common stock in connection with at-the-market offering (net of issuance costs of $84)

$ 1

1,443

1,444

Issuance of common stock in connection with at-the-market offering (net of issuance costs of $84) (in Shares)

^[1]

133,521

Stock-based compensation

1,389

Issuance of common stock under equity plan awards

Issuance of common stock under equity plan awards (in Shares)

^[1]

3,649

Net loss

(10,860)

Balance at Mar. 31, 2025

$ 4

229,095

(217,966)

11,133

Balance (in Shares) at Mar. 31, 2025

^[1]

3,519,602

Balance at Dec. 31, 2024

$ 3

226,229

(207,106)

19,126

Balance (in Shares) at Dec. 31, 2024

^[1]

3,382,432

Statement [Line Items]

Net loss

(22,241)

Balance at Sep. 30, 2025

$ 4

235,689

(229,347)

6,346

Balance (in Shares) at Sep. 30, 2025

^[1]

4,440,161

Balance at Mar. 31, 2025

$ 4

229,095

(217,966)

11,133

Balance (in Shares) at Mar. 31, 2025

^[1]

3,519,602

Statement [Line Items]

Issuance of common stock for cash (net of issuance costs)

3,570

Issuance of common stock for cash (net of issuance costs) (in Shares)

^[1]

584,253

Issuance of pre-funded warrants (net of issuance costs)

1,858

Issuance of pre-funded warrants (net of issuance costs) (in Shares)

^[1]

334,000

Stock-based compensation

1,092

Net loss

(7,870)

Balance at Jun. 30, 2025

$ 4

235,615

(225,836)

9,783

Balance (in Shares) at Jun. 30, 2025

^[1]

4,437,855

Statement [Line Items]

Stock-based compensation

Issuance of common stock under equity plan awards

Issuance of common stock under equity plan awards (in Shares)

^[1]

2,306

Net loss

(3,511)

Balance at Sep. 30, 2025

$ 4

235,689

(229,347)

6,346

Balance (in Shares) at Sep. 30, 2025

^[1]

4,440,161

Balance at Dec. 31, 2025

$ 5

240,031

(233,368)

6,668

Balance (in Shares) at Dec. 31, 2025

4,927,161

Statement [Line Items]

Issuance of common stock for payment of acquisition

$ 8

19,919

19,927

Issuance of common stock for payment of acquisition (in Shares)

8,268,495

Issuance of common stock for cash (net of issuance costs)

170

Issuance of common stock for cash (net of issuance costs) (in Shares)

231,482

Issuance of pre-funded warrants (net of issuance costs)

340

Issuance of pre-funded warrants (net of issuance costs) (in Shares)

Issuance of common stock warrants (net of issuance cost of $136)

762

Issuance of common stock to related parties for cash (net of issuance costs of $30)

170

Issuance of common stock to related parties for cash (net of issuance costs of $30) (in Shares)

231,482

Issuance of common stock warrants to related parties (net of issuance cost of $45)

254

Common stock warrant dividend

9,008

(9,008)

Exercise of pre-funded warrants

$ 1

Exercise of pre-funded warrants (in Shares)

685,414

Stock-based compensation

226

Net loss

(27,696)

Balance at Mar. 31, 2026

$ 14

270,880

(270,072)

822

Balance (in Shares) at Mar. 31, 2026

14,344,034

Balance at Dec. 31, 2025

$ 5

240,031

(233,368)

6,668

Balance (in Shares) at Dec. 31, 2025

4,927,161

Statement [Line Items]

Net loss

(36,569)

Balance at Sep. 30, 2026

$ 17

277,098

(278,945)

(1,830)

Balance (in Shares) at Sep. 30, 2026

16,889,767

Balance at Mar. 31, 2026

$ 14

270,880

(270,072)

822

Balance (in Shares) at Mar. 31, 2026

14,344,034

Statement [Line Items]

Issuance of common stock for warrant inducement (net of issuance costs of $289)

$ 1

1,737

1,738

Issuance of common stock for warrant inducement (net of issuance costs of $289) (in Shares)

1,172,414

Exercise of pre-funded warrants

$ 1

Exercise of pre-funded warrants (in Shares)

462,963

Stock-based compensation

(117)

Contribution of services from related party

1,710

Net loss

(5,244)

Balance at Jun. 30, 2026

$ 16

274,210

(275,316)

(1,090)

Balance (in Shares) at Jun. 30, 2026

15,979,411

Statement [Line Items]

Issuance of common stock to Lincoln Park as commitment fee

$ 1

655

656

Issuance of common stock to Lincoln Park as commitment fee (in Shares)

560,356

Issuance of common stock under Equity Line of Credit

334

Issuance of common stock under Equity Line of Credit (in Shares)

350,000

Issuance of pre-funded warrants (net of issuance costs)

649

Issuance of pre-funded warrants (net of issuance costs) (in Shares)

Issuance of Series C common stock warrants (net of issuance costs of $217)

615

Issuance of Series D common stock warrants (net of issuance costs of $205)

581

Stock-based compensation

Net loss

(3,629)

Balance at Sep. 30, 2026

$ 17

$ 277,098

$ (278,945)

$ (1,830)

Balance (in Shares) at Sep. 30, 2026

16,889,767

[1]	Shares issued and outstanding have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2026

Stock-Based Compensation [Line Items]

Summary of Stock Options

The following shows the stock option activities for the nine months ended September 30, 2026 and 2025:

	Total Options Outstanding			Weighted-Average Exercise Price
Balance—December 31, 2025		450,104		$	64.44
Granted		522,541			2.03
Exercised		—			—
Cancelled and forfeited		(405,879	)		40.17
Balance—September 30, 2026		566,766		$	23.91

Balance—December 31, 2024		320,013		$	86.06
Granted		130,091			11.20
Exercised		—			—
Cancelled and forfeited		—			—
Balance—September 30, 2025		450,104		$	64.44

Summary of Information About Stock Options Outstanding

The following table summarizes information about stock options outstanding at September 30, 2026:

	Shares		Weighted Average Remaining Contractual Life (In Years)		Weighted Average Exercise Price		Aggregate Intrinsic Value
Options outstanding		566,766		5.98	$	23.91	$	—
Vested and expected to vest		566,766		5.98	$	23.91	$	—
Exercisable		221,999		0.60	$	57.68	$	—

Schedule of Stock Based Compensation Expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Research and development	$	3	$	9	$	8	$	979
General and administrative		51		52		155		1,563
Total	$	54	$	61	$	163	$	2,542

Share-based Payment Arrangement, Employee [Member]

Stock-Based Compensation [Line Items]

Summary of Grant Date Fair Value

The fair value of employee and non-employee stock options was estimated using the following assumptions for the nine months ended September 30, 2026 and 2025:

	2026			2025
Expected term (in years)		6.1			6.0
Expected volatility	135%-152		%	115%-116		%
Risk-free interest rate		4.0	%		4.4	%
Dividends		—	%		—	%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Organization and Description of the Business

9 Months Ended

Sep. 30, 2026

Organization and Description of the Business [Abstract]

ORGANIZATION AND DESCRIPTION OF THE BUSINESS

1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Description of Business

Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease. Tempest’s product candidates leverage two proprietary CD7-targeting technology platforms: a lentiviral vector platform and an mRNA/lipid nanoparticle (LNP) platform.

Tempest’s most advanced program is TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate being evaluated in an ongoing Phase 1 dose-escalation study for relapsed or refractory multiple myeloma, including in patients with extramedullary disease and prior CAR-T exposure.

The company is also developing TPST-4003, a CD19/BCMA dual-targeting in vivo CAR-T candidate being evaluated for the treatment of autoimmune diseases. TPST-4003 incorporates a clinically supported dual-targeting parallel CAR structure designed to enable broad B-cell lineage reset across multiple indications. The company plans to evaluate TPST-4003 in an investigator-initiated trial in China in approximately 10 patients with myasthenia gravis or multiple sclerosis.

Tempest is headquartered in Brisbane, California.

Reverse Stock Split

On December 3, 2024, the Company’s stockholders approved a proposal to effect an amendment to the Company’s Restated Certificate of Incorporation to implement a reverse stock split. On April 4, 2025, the Company filed a certificate of amendment to the Company’s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the one-for-thirteen (1:13) reverse stock split of its outstanding common stock (the “Reverse Stock Split”).

On April 8, 2025, the Company effected the Reverse Stock Split. Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company’s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company’s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.

No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder’s percentage ownership of the Company’s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share).

Liquidity and Going Concern

The Company has incurred operating losses since inception. As of September 30, 2026, the Company had $0.9 million of cash and cash equivalents. While the Company implemented cost reductions in 2025, the Company has finite cash resources available to fund its operations.

In April 2025, the Company announced plans to explore a full range of strategic alternatives to advance its clinical-stage programs and maximize stockholder value. The Company retained MTS Health Partners, L.P., a financial advisor with experience in the biotechnology industry, to support the strategic evaluation process. In connection with these efforts and related cost-reduction measures, the Company reduced its workforce by 21 of 26 full-time employees, effective April 30, 2025. On June 5, 2025, Stephen Brady, the Company’s then-Chief Executive Officer and President, Samuel Whiting, the Company’s then-Executive Vice President and Chief Medical Officer, and Nicholas Maestas, the Company’s then-Chief Financial Officer and Head of Corporate Strategy, transitioned to consulting arrangements with the Company and continued to serve in their respective executive roles at that time. The Company incurred $3.2 million of one-time cash severance payments, benefits and other related costs, excluding non-cash charges associated with stock-based compensation, with the majority of such costs incurred during the third quarter of 2025. Between June and September 2026, the Company further reduced its workforce by three of four full-time employees, supported by external consultants and service providers.

On February 3, 2026, the Company closed the Asset Acquisition (as defined below). Pursuant to the Asset Purchase Agreement (as defined below), Factor (as defined below) has made the Funding Commitment (as defined below) to provide the Company with financial support until the earlier to occur of (i) 18 months following the closing of the Asset Acquisition and (ii) the receipt by the Company of at least $20.0 million in gross proceeds from the sale of its equity or debt securities, up to a maximum amount of $20.0 million that is inclusive of any amounts raised and received by the Company after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement. However, there is significant uncertainty as to whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. The timing of any additional funding from Factor is uncertain. As of September 30, 2026, $8.9 million of availability remained under the Funding Commitment.

Further, as detailed below under “Private Placements,” “Registered Direct Offering and Warrant Inducement,” and “Equity Line of Credit”, the Company has undertaken other steps to increase its cash and cash equivalents. On March 20, 2026, the Company entered into a securities purchase agreement for the sale of securities for approximately $2.0 million in gross proceeds (excluding up to approximately $4.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of common warrants issued thereunder), before deducting placement agent fees and other offering expenses payable by the Company. On May 28, 2026, the Company further entered into a warrant exercise and inducement letter agreement with the holder of certain existing warrants originally issued in November 2025, for the exercise of existing warrants at a reduced exercise price of $1.73 per share, resulting in gross proceeds to the Company of approximately $2.0 million (excluding up to approximately $4.2 million of aggregate gross proceeds that may be received in the future upon the cash exercise of new warrants issued in connection therewith). On August 13, 2026, the Company entered into a purchase agreement that gives the Company the right, but not the obligation, to sell up to $25.0 million of its common stock to an investor, increasing to $50.0 million if the initial amount is sold, under which the Company has sold $0.3 million in gross proceeds as of September 30, 2026. On September 11, 2026, the Company entered into another securities purchase agreement, for the sale of securities for approximately $2.5 million in gross proceeds (excluding up to approximately $5.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of common warrants issued thereunder), before deducting placement agent fees and other offering expenses payable by the Company.

The Company expects that its existing cash and cash equivalents will fund the Company’s projected operating expense requirements through less than 12 months from the date our condensed consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.

The Company is actively exploring a range of options to raise additional funds.

Acquisition of Erigen Assets

On November 19, 2025, the Company executed an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Erigen LLC, a Delaware limited liability company (“Erigen”), and Factor Bioscience Inc., a Delaware corporation (“Factor,” and together with Erigen, “Sellers”), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers in and to all of the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as TPST-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as TPST-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as TPST-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as TPST-3206 (collectively referred to herein as the “Erigen Assets”), in exchange for an aggregate purchase price of 8,268,495 shares of the Company’s common stock to be issued to Erigen on behalf of both Sellers.

On February 3, 2026, the Company completed the acquisition of the Erigen Assets (the “Erigen Closing”) under the Asset Purchase Agreement (the “Asset Acquisition”) and issued to Erigen 8,268,495 shares of the Company’s common stock. Based on the closing price of the Company’s common stock price of $2.41 per share on February 3, 2026, the aggregate fair value of equity issued in the Asset Acquisition was approximately $19.9 million.

The Company accounted for the Asset Acquisition as an asset acquisition. In addition to the $19.9 million in aggregate fair value of equity issued, approximately $2.2 million in transaction costs were capitalized as part of the total cost of the Asset Acquisition, totaling $22.1 million expensed as acquired in-process research and development during the three months ended March 31, 2026. During the year ended December 31, 2025, approximately $2.2 million of transaction costs were incurred and expensed as General and administrative expense prior to the closing of the Asset Acquisition. The fair value of the shares issued was recorded as an increase to common stock (at par) and additional paid-in capital on the date of the Erigen Closing.

Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the “Funding Commitment”) to provide the Company with financial support until the earlier to occur of (i) 18 months following the Erigen Closing and (ii) the receipt by the Company of at least $20.0 million in gross proceeds from the sale of its equity or debt securities, up to a maximum amount of $20.0 million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement.

In November 2025, Erigen entered into an Amended and Restated Master Services Agreement with Factor (the “Factor MSA”), which was assigned to the Company in connection with the Erigen Closing pursuant to the Asset Purchase Agreement. Under the Factor MSA, the Company is obligated to pay Factor a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the Factor MSA or any work order at any time upon 30 days’ prior written notice and immediately upon written notice if Factor breaches the Factor MSA or any work order, as the case may be, and does not fully cure the breach to the Company’s satisfaction within 30 days. Upon termination any work order, unless the applicable work order expressly provides otherwise, the Company will pay Factor fees for all services performed and reimburse Factor for all authorized, non-cancellable expenses reasonably incurred in connection with such services prior to termination.

In March 2026 the Board of the Company approved and authorized the execution of Work Order No. 1 under the Factor MSA for R&D services beginning April 2026. Under this agreement, the Company is committed to pay Factor for services through March 31, 2027. In April 2026, the Company paid Factor a deposit of $0.4 million under Work Order No. 1 of the Factor MSA primarily related to the clinical advancement of TPST-2003.

On May 12, 2026, the Company entered into a letter agreement (the “Letter Agreement”) with Factor relating to certain payment obligations of the Company under the Factor MSA and Work Order No. 1 (the “Work Order”). Pursuant to the Letter Agreement, Factor agreed to permanently waive its right to receive the first $2.1 million payable by the Company to Factor under the Factor MSA and the Work Order. Accordingly, as of September 30, 2026, no amounts were payable under this arrangement. $1.7 million of research and development expense was incurred under Work Order No. 1 during the nine months ended September 30, 2026. No services were invoiced after June 30, 2026, and the remaining $0.4 million of the waiver has not been used.

In addition, Factor agreed to return to the Company $0.2 million of the deposit previously made by the Company under the Work Order, for an interim period subject to certain conditions.

On September 22, 2026, the Company entered into a Master Services Agreement with Factor (the “2026 Factor MSA”) and Work Order No. 1 (the “2026 Work Order”), which the Audit Committee approved as a related party transaction. Under the 2026 Work Order, Factor provides research and development services for TPST-4003, TPST-4903 and the Senlang collaboration for a fixed fee of $5.0 million per year, payable monthly, plus third-party costs and a 10% project management fee. Either party may terminate on 30 days’ written notice. The 2026 Factor MSA supports Tempest’s development activities, including its obligations under the Amended and Restated License and Collaboration Agreement between Tempest and Factor Bioscience Limited, Factor’s Irish subsidiary, dated November 19, 2025 and effective as of August 6, 2025, which was assigned to the Company in connection with the Erigen Closing pursuant to the Asset Purchase Agreement. The Letter Agreement waiver does not apply to the 2026 Factor MSA. The Company recognized $0.1 million of research and development expense under the 2026 Work Order during the three months ended September 30, 2026, which is included in accrued expenses. See Note 13.

Warrant Dividend

On January 20, 2026, the Company’s Board of Directors declared a record date of January 30, 2026 (the “Record Date”), for the distribution of a dividend (the “Warrant Dividend”) in the form of a warrant to purchase a share of the Company’s common stock (collectively, the “Warrants”) for each share of common stock outstanding on the Record Date at an exercise price of $18.48 per share. The Warrants were issued on the terms and conditions described in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent, on February 3, 2026. In addition, on February 3, 2026, certain warrants that were outstanding on the Record Date also received Warrants on a one-for-one basis, pursuant to the terms of such warrants (together with the Warrant Dividend, the “Warrant Distribution”). In the aggregate, 6,784,989 Warrants were issued pursuant to the Warrant Distribution.

Private Placements

On March 20, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with (a) two institutional investors (the “Institutional Investors”) and (b) Factor (together with the Institutional Investors, each, an “Investor” and, together, the “Investors”), pursuant to which the Company agreed to issue and sell in a private placement (the “March 2026 Private Placement”) an aggregate of 462,964 shares (the “Shares”) of the Company’s common stock, and, in lieu of common stock, pre-funded warrants to purchase up to 462,963 shares of common stock (the “March Pre-Funded Warrants”), in each case accompanied by (i) Series A warrants to purchase up to 925,927 shares of common stock (the “Series A Warrants”) and (ii) Series B warrants to purchase up to 925,927 shares of common stock (the “Series B Warrants” and, together with the Series A Warrants, the “March Common Warrants”). The Shares, March Pre-Funded Warrants and March Common Warrants are immediately separable and were issued separately. The combined purchase price per Share and accompanying March Common Warrants was $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying March Common Warrants was $2.159. The gross proceeds to the Company from the March 2026 Private Placement were approximately $2.0 million (excluding up to approximately $4.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of the March Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company. All March Pre-Funded Warrants were subsequently exercised in April 2026.

The Series A Warrants became exercisable on June 18, 2026, the effective date of the Stockholder Approval (the “Stockholder Approval Date”) and have a term of five years from such date. The Series B Warrants became exercisable on the Stockholder Approval Date and have a term of twenty-four months thereafter. The March Common Warrants have an exercise price of $2.16 per share.

In connection with the March 2026 Private Placement, the Company entered into a registration rights agreement with the Investors, pursuant to which the Company agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the March 2026 Private Placement and the shares of the Company’s common stock underlying the March Common Warrants and March Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a “full review” by the SEC. The registration statement was filed on April 2, 2026 and declared effective on April 9, 2026.

On September 11, 2026, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company sold, in a private placement that closed on September 15, 2026 (the “September 2026 Private Placement”), pre-funded warrants to purchase 3,105,591 shares of common stock (“September Pre-Funded Warrants”), accompanied by Series C Warrants to purchase up to 3,105,591 shares of Common Stock (“Series C Warrants”) and Series D Warrants to purchase up to 3,105,591 shares of Common Stock (“Series D Warrants” and, together with the Series C Warrants, the “September Common Warrants”). The September Pre-Funded Warrants and September Common Warrants are immediately separable and were issued separately. The combined purchase price per Pre-Funded Warrant and accompanying September Common Warrants was $0.804. The gross proceeds to the Company from the September 2026 Private Placement were approximately $2.5 million (excluding up to approximately $5.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of the September Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company. All September Pre-Funded Warrants were subsequently exercised in October 2026. See Note 7.

The Series C Warrants and Series D Warrants became exercisable on November 9, 2026, the effective date of the Stockholder Approval, and each have a term of six years and three years therefrom, respectively. The September Common Warrants have an exercise price of $0.805 per share.

In connection with the September 2026 Private Placement, the Company entered into a registration rights agreement with the Investors, pursuant to which the Company agreed to file a registration statements under the Securities Act with the SEC covering the resale of the shares of the Company’s common stock underlying the September Common Warrants and the September Pre-Funded Warrants no later than 15 calendar days following the date of the purchase agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following such date, and in any event no later than 75 calendar days following such date in the event of a “full review” by the SEC. The registration statement was filed on September 25, 2026 and declared effective on October 1, 2026.

ATM Program

On July 23, 2021, the Company entered into a sales agreement with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to time at its sole discretion through Jefferies, as its sales agent, shares of its common stock having, up to an aggregate sales price of $100.0 million of its common stock through Jefferies (the “Prior ATM Program”). As of June 20, 2024, the Company had sold an aggregate 9,017,110 shares of its common stock for gross proceeds of $42.7 million ($41.5 million net of commissions and estimated expenses) under the Prior ATM Program. On June 20, 2024, the Company and Jefferies terminated the Prior ATM Program and entered a new Open Market Sale Agreement (the “Sales Agreement”) to sell shares of common stock from time to time through Jefferies acting as sales agent (the “ATM Program”). The Company will pay Jefferies a commission up to 3.0% of the gross sales proceeds of any shares of its common stock sold through Jefferies under the ATM Program and also has provided Jefferies with indemnification and contribution rights. Pursuant to the prospectus supplement dated June 20, 2024 filed by the Company with the U.S. Securities and Exchange Commission (“SEC”), the Company was able to offer and sell up to $205.0 million of its shares of common stock pursuant to the Sales Agreement. On February 6, 2025, the Company filed a prospectus supplement with the SEC limiting the availability under the ATM Program to $14.5 million. On June 11, 2025, in connection with the RDO (as defined below), the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the “ATM Prospectus”). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.

Under current SEC regulations, if at any time the Company’s public float is less than $75.0 million, and for so long as the Company’s public float remains less than $75.0 million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company’s public float, which is referred to as the baby shelf rules. As of the three and nine months ended September 30, 2026, the Company has not sold any shares, pursuant to the ATM Program. As of the date of this Form 10-Q, the Company’s public float was approximately $10.2 million, which limits capacity under the shelf registration statement to approximately $3.4 million in any 12-month period, including any sales under the ATM Program.

Registered Direct Offering and Warrant Inducement

On November 24, 2025, the Company sold an aggregate of 487,000 shares of the Company’s common stock, pre-funded warrants to purchase 685,414 shares of its common stock (the “November 2025 Pre-Funded Warrants”) and warrants to purchase an aggregate of 1,172,414 shares of common stock (the “November 2025 Common Warrants”) in a registered direct offering (the “November RDO”). The combined purchase price of each share of common stock and accompanying November 2025 Common Warrant was $3.625. The combined purchase price of each November 2025 Pre-Funded Warrants and accompanying November 2025 Common Warrants was $3.624 (equal to the combined purchase price per share of common stock and accompanying November 2025 Common Warrant, minus $0.001). The exercise price of the November 2025 Common Warrants is $3.50 per share. The net proceeds from the November RDO were approximately $3.8 million, after deducting placement agent fees and estimated offering expenses payable by the Company. As of September 30, 2026, all November 2025 Pre-Funded Warrants had been exercised.

On May 28, 2026, the Company entered into an inducement agreement with the holder of the November 2025 Common Warrants, which were exercisable for 1,172,414 shares of common stock at an exercise price of $3.50 per share and were classified within stockholders’ equity (deficit). To induce the holder to exercise the November 2025 Common Warrants for cash, the Company reduced the exercise price of the November 2025 Common Warrants to $1.73 per share and agreed to issue to the holder new warrants to purchase up to 2,344,828 shares of common stock at an exercise price of $1.73 per share (the “New Warrants”). The holder exercised the November 2025 Common Warrants in full for aggregate gross proceeds of approximately $2.0 million.

The reduction of the exercise price of the November 2025 Common Warrants and the issuance of the New Warrants were undertaken to induce the cash exercise of the November 2025 Common Warrants and thereby raise equity capital. The Company measured the effect of the modification as the increase in fair value resulting from the modification using a Black-Scholes option pricing model, comprising the $2.0 million fair value of the New Warrants, measured as of the May 29, 2026 issuance date, and the $0.4 million incremental fair value of the November 2025 Common Warrants attributable to the reduction in exercise price, measured as of the May 28, 2026 modification date, for a total of $2.4 million. In accordance with ASC 815-40-35-17 and ASC 340-10-S99-1, the Company accounted for this amount as an equity issuance cost recorded as a reduction of additional paid-in capital, offset by the recognition of the New Warrants within additional paid-in capital. The modification resulted in no net change to total stockholders equity (deficit)and no charge to net loss or to net loss attributable to common stockholders. As of September 30, 2026, no November 2025 Common Warrants remained outstanding. The New Warrants became exercisable upon receipt of stockholder approval under applicable Nasdaq rules and will expire on May 29, 2028. In June 2026, pursuant to a registration rights agreement entered into in connection with the May 2026 warrant exercise inducement transaction, the Company filed a resale registration statement on Form S-3 with the SEC covering up to 2,426,897 shares of the Company’s common stock issuable upon exercise of the New Warrants and the placement agent warrants issued in connection with the transaction. The registration was declared effective on July 7, 2026.

In connection with the transaction, the Company issued to the placement agent warrants to purchase 82,069 shares of common stock at an exercise price of $2.1625 per share (the “Placement Agent Warrants”), with a grant-date fair value of $0.1 million, recorded as an equity issuance cost and a corresponding increase to additional paid-in capital, with no net effect on total stockholders’ equity (deficit).

Equity Line of Credit

On August 13, 2026, the Company entered into a purchase agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) that gives the Company the right, but not the obligation, to sell up to $25.0 million of its common stock to Lincoln Park, increasing to $50.0 million if the initial amount is sold (the “ELOC”). Sales are subject to conditions and limitations, including a minimum price of $0.15 per share, pricing formulas, volume caps, the effectiveness of a registration statement registering the resale by Lincoln Park of shares of common stock issued by the Company to Lincoln Park under the Lincoln Park Purchase Agreement. Additionally, the Company may not direct Lincoln Park to purchase any shares of common stock if such purchase would result in Lincoln Park beneficially owning more than 4.99% of the issued and outstanding shares of common stock. The sales may occur from time to time, at the Company’s sole discretion, over a period of up to 24-months from the commencement of sales under the Lincoln Park Purchase Agreement, which took place on September 1, 2026.

Pursuant to the terms of the Lincoln Park Purchase Agreement and a registration rights agreement entered into in connection therewith, the Company filed a registration statement with the SEC on August 21, 2026 covering the resale of up to 8,000,000 shares of Common Stock the Company may issue and sell to Lincoln Park from time to time, at its sole discretion, as well as certain commitment shares issued to Lincoln Park as consideration for its commitment to purchase shares of common stock under the Lincoln Park Purchase Agreement. There is no assurance when the Company might be able to make sales to Lincoln Park in the future. Through September 30, 2026, the Company sold 350,000 shares to Lincoln Park for gross proceeds of approximately $0.3 million. See Note 7.

Related Party Transactions (Details) - USD ($)
$ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 22, 2026

May 12, 2026

Apr. 01, 2026

Mar. 31, 2026

Nov. 30, 2025

Sep. 30, 2026

Mar. 31, 2026

Jun. 30, 2025

^[1]

Sep. 30, 2026

Apr. 30, 2026

Related party payable

$ 100

Waiver amount payable under Factor MSA

$ 2,100

Waiver accounted for capital contribution

2,100

Service fee waiver

1,700

Advisory fees

300

400

Research and development expense

100

Accrued payments

100

General and administrative expense

400

Funding commitment

8,900

$ 8,900

Remaining waiver fees

400

Common Stock [Member]

Shares issued in transaction

8,000,000

Purchase price

231,482

584,253

Factor Bioscience Inc. [Member]

Research and development expense

100

$ 1,800

Factor Bioscience Inc. [Member] | Common Stock [Member]

Purchase price

8,268,495

Dr. Angel [Member]

Related party payable

$ 416,667

Ownership percentage after issuance

37.00%

Monthly installments

$ 5,000

Project management fee percentage

10.00%

Lotus Capital BVI Limited [Member]

Ownership percentage after issuance

26.00%

Erigen [Member]

Legal fees

$ 400

Shares issued in transaction

8,268,495

Asset Purchase Agreement [Member]

Deposits of related parties

$ 400

Prepaid and other expense

400

$ 400

Letter Agreement [Member]

Waiver amount payable under Factor MSA

$ 2,100

Deposits considered

$ 200

Advisory Agreement

Service fees

$ 720,000

Beneficial owner percentage

5.00%

Advisory Agreement | Andrew Fang [Member]

Service fees

$ 1,250

Advisory Agreement | YQ Service Providers [Member]

Service fees

$ 250

Restated Factor License Agreement [Member]

Development milestones payment

$ 40,000

Commercial milestone payment

$ 620,000

Private Placement [Member]

Shares issued in transaction

231,482

Private Placement [Member] | Warrant [Member]

Exchange of warrants

$ 500

Private Placement [Member] | Series B Warrants [Member]

Share of warrants

231,482

Private Placement [Member] | Series A Warrants [Member]

Share of warrants

231,482

[1]	Shares issued and outstanding have been adjusted to reflect the one-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Operating activities:
Net loss	$ (36,569)	$ (22,241)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	176	201
Stock-based compensation expense	163	2,542
Non-cash lease expense	898	818
Non-cash interest and other expense, net	652	77
Research and development expense funded by related party contribution of services	1,710
Acquired in-process research and development	19,927
Changes in operating assets and liabilities:
Prepaid expenses and other assets	285	582
Accounts payable	993	(1,528)
Accrued expenses and other liabilities	219	(3,032)
Interest payable		(59)
Operating lease liabilities	(883)	(606)
Cash used in operating activities	(12,429)	(23,246)
Investing activities:
Cash used in investing activities
Financing activities:
Proceeds from the issuance of common stock, pre-funded warrants and common stock warrants, net of issuance costs	5,195	6,871
Proceeds from the issuance of common stock and common stock warrants to related party, net of issuance costs	424
Repayment of loan		(6,426)
Proceeds from the issuance of common stock under equity plan awards		47
Cash provided by financing activities	5,619	492
Net decrease in cash, cash equivalents and restricted cash	(6,810)	(22,754)
Cash, cash equivalents and restricted cash at beginning of period	7,707	30,711
Cash, cash equivalents and restricted cash at end of period	897	7,957
Supplemental disclosure of cash flow information:
Cash paid for interest		192
Cash paid for business taxes	$ 104	$ 43

Balance Sheet Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Balance Sheet Components [Abstract]
Depreciation expense	$ 57	$ 66	$ 176	$ 201

Commitments and Contingencies

9 Months Ended

Sep. 30, 2026

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

5. COMMITMENTS AND CONTINGENCIES

Facilities Lease Agreements

In January 2022, the Company entered into an 8-year office lease agreement for a 20,116 square feet facility in Brisbane, California (“Brisbane Lease”). The lease commenced in December 2022.

As of September 30, 2026 and December 31, 2025, the balance of the operating lease right of use assets were $6,642 and $7,540, respectively, and the related operating lease liabilities were $7,258 and $8,141, respectively, as shown in the accompanying condensed consolidated balance sheets.

Rent expense was $491 and $1,459 for the three and nine months ended September 30, 2026, respectively. Rent expense was $486 and $1,459 for the three and nine months ended September 30, 2025, respectively.

As of September 30, 2026, future minimum lease payments under the Company’s operating lease liabilities were as follows:

Year Ending	Total Commitment
2026 (excluding nine months ended September 30, 2026)	$	482
2027		1,994
2028		2,064
2029		2,136
2030		2,210
Total minimum lease payments		8,886
Less: imputed interest		(1,628	)
Present value of operating lease obligations		7,258
Less: current portion		(1,336	)
Noncurrent operating lease obligations	$	5,922

Related to this Brisbane Lease agreement, the Company entered into a letter of credit with a bank to deposit $388 in a separate account that is classified as restricted cash to serve as security rent deposit. In August 2026, the letter of credit was terminated and the $388 deposit was released to the Company and reclassified to cash. The landlord applied the security deposit to unpaid rent and has required the Company to replenish it, which the Company has not done. The Company has not modified or amended the Brisbane Lease or deferred any rent payments, and the Brisbane Lease remains in effect. See Note 14 for rent outstanding after September 30, 2026. As of September 30, 2026, the Company had no significant restricted cash.

Hebei Senlang Biotechnology Co., Ltd.

In July 2026, the Company entered into a three-year Product Development and Investigator-Initiated Trial (“IIT”) Collaboration Agreement (the “Collaboration Agreement”) with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”). Under the Collaboration Agreement, Senlang may perform product development, manufacturing and IIT-related activities in China for certain of the Company’s in vivo CAR-T product candidates pursuant to product-specific statements of work (“SOWs”). For each SOW, the Company will pay Senlang a development fee of between $1.5 million and $2.0 million, with the payment schedule set forth in the SOW. The Company retains ownership of its product candidates and related intellectual property. Following completion of a SOW and delivery of the related data package, Senlang has a 90-day exclusive option to negotiate a license for the relevant product candidate in China on terms mutually agreeable to the parties. As of September 30, 2026, no SOW had been executed, and no services had been performed or payments made.

In September 2026, the Company entered into an Exclusive Collaboration, Option and License Agreement (the “Option Agreement”) with Senlang, under which Senlang granted the Company an exclusive option, exercisable through January 14, 2027, to obtain an exclusive, royalty-bearing license to Senlang’s in vivo CAR-T technology outside Greater China. No payment is due upon entrance into the option agreement. If the Company exercises the option, it will be required to pay an initial license fee of RMB 3.0 million, annual maintenance fees of $10.0 million, $12.0 million and $14.0 million in the first three years, respectively, a 6% royalty on net sales and a share of any sublicense revenue. As of September 30, 2026, the Company had not exercised the option; the Company exercised the option on November 11, 2026 (see Note 14). Accordingly, as of September 30, 2026, no amounts related to the Collaboration Agreement or the Option Agreement have been recognized in the accompanying condensed consolidated financial statements. The Company is evaluating the accounting for the license.

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2026

Net Loss Per Share [Abstract]

Schedule of Basis in Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three and nine months ended September 30, 2026 and 2025 (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Numerator:
Net loss	$	(3,629	)	$	(3,511	)	$	(36,569	)	$	(22,241	)
Denominator:
Weighted-average common shares outstanding		16,910,029			4,440,111			14,377,097			3,897,256
Weighted-average shares used in computing basic and diluted net loss per share		16,910,029			4,440,111			14,377,097			3,897,256
Net loss per share attributable to common stockholders—basic and diluted	$	(0.21	)	$	(0.79	)	$	(2.54	)	$	(5.71	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Based on the amounts outstanding as of September 30, 2026 and 2025, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect, as adjusted to give effect to the reverse stock split:

	As of September 30,
	2026		2025
Options to purchase common stock		566,766		450,104
Common stock warrants		17,492,777		464
Total		18,059,543		450,568

Subsequent Events

9 Months Ended

Sep. 30, 2026

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

Exercise of Pre-Funded Warrants

On October 2, 2026, the holder of the pre-funded warrants issued in the September 2026 private placement exercised all 3,105,591 pre-funded warrants at an exercise price of $0.001 per share for cash proceeds of approximately $3 thousand. The Company issued 3,105,591 shares of common stock, and no pre-funded warrants from the September 2026 private placement remain outstanding.

Rights Agreement

On October 10, 2026, the Rights Agreement expired in accordance with its terms, and the Rights are no longer outstanding.

Vendor Settlement Agreement

On October 27, 2026, the Company entered into a settlement agreement with a service provider to resolve an outstanding balance of approximately $0.7 million for $0.2 million, payable in two installments of $0.1 million on November 30, 2026 and December 31, 2026. The service provider’s release of the remaining balance is conditional on timely receipt of both payments and the absence of a bankruptcy filing or assignment for the benefit of creditors within 91 days after the final payment. Because the release will not be effective until that period expires, the Company has not derecognized the liability and expects to recognize a gain of approximately $0.5 million, net of the payments made, in the quarter in which the release becomes effective.

Brisbane Lease

As of November 4, 2026, the Company had approximately $0.2 million of unpaid rent under the Brisbane Lease (see Note 5). The landlord applied the security deposit to unpaid rent and has required the Company to replenish it, which the Company has not done. As of the date these financial statements were issued, the landlord has not exercised any remedies under the lease.

Share Issuance Approval

On November 9, 2026, the Company held its annual meeting of stockholders, at which stockholders approved, among others, the issuance of the shares of common stock underlying the September Common Warrants, as well as the issuance of more than 3,195,881 shares of common stock under the Lincoln Park Purchase Agreement.

Exercise of Senlang Option

On November 11, 2026, the Company exercised its option under the Option Agreement with Senlang (see Note 5) to obtain an exclusive, royalty-bearing license to Senlang’s in vivo CAR-T technology outside Greater China. Under the Option Agreement, the Company is required to pay an initial license fee of RMB 3.0 million, annual maintenance fees of $10.0 million, $12.0 million and $14.0 million in the first three years, respectively, a 6% royalty on net sales and a share of any sublicense revenue. The Company is evaluating the accounting for the license.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Stockholders' Equity (Deficit) (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Oct. 10, 2023	Sep. 30, 2026	Nov. 09, 2026	Sep. 11, 2026	Aug. 13, 2026	Dec. 31, 2025	Jun. 30, 2025
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares authorized		100,000,000				100,000,000
Common stock, par value (in dollars per share)		$ 0.001				$ 0.001
Common stock value		$ 17				$ 5
Price per share		$ 0.15
Common stock, shares issued		16,889,767				4,927,161
Additional shares		350,223
Issuance costs		$ 150
Gross proceeds		300
Additional paid-in capital		277,098				$ 240,031
Purchase price		150
Liabilities		$ 10,591				$ 10,263
Subsequent Event [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued			3,195,881
O 2023 Q4 Dividends [Member]
Stockholders' Equity (Deficit) [Line Items]
Dividend record date	Oct. 23, 2023
Equity Line of Credit [Member]
Stockholders' Equity (Deficit) [Line Items]
Price per share					$ 1.3854
Shares outstanding percentage		19.99%
Lincoln Park [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock value		$ 25,000
Common stock, shares issued		560,356
Lincoln Park [Member] \| Equity Line of Credit [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock value		$ 25,000
Common stock, shares issued					3,195,881
Maximum [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock value		$ 50,000
Issuance costs					$ 50,000
Cash liquidated damages, percentage		6.00%
Minimum [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock value					25,000
Issuance costs					$ 25,000
Cash liquidated damages, percentage		1.00%
Series A Participating Preferred Stock [Member] \| Rights Plan [Member]
Stockholders' Equity (Deficit) [Line Items]
Preferred stock price per share	$ 25
Common Stock [Member] \| Lincoln Park [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued		350,000
Series D Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Additional paid-in capital		$ 800
Series C Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, par value (in dollars per share)		$ 1.0063
Common stock, shares issued		217,391
Additional paid-in capital		$ 800
Pre-Funded Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Additional paid-in capital		900
Fair Value [Member]
Stockholders' Equity (Deficit) [Line Items]
Issuance costs		$ 660
Fair Value [Member] \| Lincoln Park [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued		560,356
Fair Value [Member] \| Series C Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Issuance costs		$ 150
September 2026 Private Placement [Member]
Stockholders' Equity (Deficit) [Line Items]
Issuance costs		650
Gross proceeds		2,500
Liquidated damages
Liabilities
September 2026 Private Placement [Member] \| Warrant [Member]
Stockholders' Equity (Deficit) [Line Items]
Price per share		$ 0.804
Exercise price per share		0.805
September 2026 Private Placement [Member] \| Series D Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued				3,105,591
September 2026 Private Placement [Member] \| Series C Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued				3,105,591
September 2026 Private Placement [Member] \| Pre-Funded Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares issued				3,105,591
Exercise price per share		$ 0.001
Authorized Stock [Member]
Stockholders' Equity (Deficit) [Line Items]
Common stock, shares authorized		100,000,000
Preferred stock, shares authorized		5,000,000
Common stock, par value (in dollars per share)		$ 0.001
Dividends
Voting rights of common stock		one
Preferred stock, par or stated value per share		$ 0.001
Authorized Stock [Member] \| Series A Participating Preferred Stock [Member]
Stockholders' Equity (Deficit) [Line Items]
Preferred stock, shares authorized		100,000
Preferred stock, shares outstanding
Ownership percentage [Member] \| Equity Line of Credit [Member]
Stockholders' Equity (Deficit) [Line Items]
Ownership percentage					4.99%
Ownership percentage [Member] \| September 2026 Private Placement [Member]
Stockholders' Equity (Deficit) [Line Items]
Ownership percentage		9.99%
Ownership percentage [Member] \| September 2026 Private Placement [Member] \| Pre-Funded Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Ownership percentage		4.99%
Ownership percentage [Member] \| September 2026 Private Placement [Member] \| Common Warrants [Member]
Stockholders' Equity (Deficit) [Line Items]
Ownership percentage		9.99%

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2026

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies—The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2026. Other than the policy for derivative liabilities described below, there have been no material changes to the significant accounting policies during the nine months ended September 30, 2026.

Basis of Presentation—The unaudited interim Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been omitted. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2025.

The Company has prepared the accompanying Condensed Consolidated Financial Statements on the same basis as the audited financial statements, and the unaudited interim condensed consolidated financial statements include, in the Company’s opinion, all adjustments, consisting only of normal recurring adjustments that the Company considers necessary for a fair presentation of its financial position and results of operations for these periods.

All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation, the valuation of warrants and other equity-linked instruments, and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.

Acquired In-Process Research and Development Expenses—Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used to determine the cost of the acquisition. Common stock issued as consideration in an acquisition of assets is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of the asset acquisition. Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in-process research and development, or IPR&D. Acquired IPR&D that has no alternative future use is expensed immediately as a component of in-process research and development expense in the condensed consolidated statements of operations.

In addition to upfront consideration, acquisitions of assets may also include contingent consideration payments to be made for future milestone events or royalties on net sales of future products. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration payments in an acquisition of assets not required to be accounted for as a liability at fair value are recognized when the contingency is resolved and the consideration is paid or becomes payable. Contingent consideration payments made prior to regulatory approval are expensed as incurred.

Derivative Liability—The Company evaluates the terms of its financing agreements to identify embedded features that may require derivative accounting under ASC 815 – Derivatives and Hedging. Derivative instruments are recorded at fair value, with changes in fair value recognized in the condensed consolidated statement of operations. The Company determined that certain settlement provisions of the Lincoln Park Purchase Agreement (see Note 7) are not indexed to the Company’s own stock, and the Lincoln Park Purchase Agreement is therefore accounted for as a derivative liability in its entirety. The derivative liability is measured at fair value, which has been deemed de minimis as of September 30, 2026. Commitment shares issued to Lincoln Park and issuance costs related to the Lincoln Park Purchase Agreement are expensed as financing costs related to the equity line of credit when incurred.

Recent Accounting Pronouncements—In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to improve disclosures about the types of expenses included in certain expense captions presented on the face of the income statement. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and related disclosures.

Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Asset (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 295	$ 207
Other current assets	417	355
Total	$ 712	$ 562

Segment Reporting (Details)	9 Months Ended
Segment Reporting (Details)	Sep. 30, 2026 Segment
Segment Reporting [Abstract]
Number of reportable segment	1
Number of operating segment	1
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer
Segment Reporting, Expense Information Used by CODM, Description	The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company’s Condensed Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company’s Condensed Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	16,889,767	4,927,161
Common stock, shares outstanding	16,889,767	4,927,161

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Net Loss Per Share

9 Months Ended

Sep. 30, 2026

Net Loss Per Share [Abstract]

NET LOSS PER SHARE

10. NET LOSS PER SHARE

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Numerator:
Net loss	$	(3,629	)	$	(3,511	)	$	(36,569	)	$	(22,241	)
Denominator:
Weighted-average common shares outstanding		16,910,029			4,440,111			14,377,097			3,897,256
Weighted-average shares used in computing basic and diluted net loss per share		16,910,029			4,440,111			14,377,097			3,897,256
Net loss per share attributable to common stockholders—basic and diluted	$	(0.21	)	$	(0.79	)	$	(2.54	)	$	(5.71	)

As of September 30, 2026 and 2025, the Company’s potentially dilutive securities included outstanding stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The shares issuable upon exercise of pre-funded warrants have been included in the computation of basic and diluted net loss per share attributable to common stockholders. Based on the amounts outstanding as of September 30, 2026 and 2025, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect, as adjusted to give effect to the reverse stock split:

	As of September 30,
	2026		2025
Options to purchase common stock		566,766		450,104
Common stock warrants		17,492,777		464
Total		18,059,543		450,568

The 350,223 shares of common stock issuable to Lincoln Park as additional consideration for its commitment under the Lincoln Park Purchase Agreement (see Note 7), only if Lincoln Park purchases $25.0 million of common stock, are contingently issuable and are excluded from the computation of basic and diluted net loss per share because the $25.0 million purchase condition had not been met as of September 30, 2026. The Company’s right to sell shares to Lincoln Park under the Lincoln Park Purchase Agreement was antidilutive for the three and nine months ended September 30, 2026 and was excluded from the computation of diluted net loss per share.

The September Common Warrants (6,211,182 shares) and the placement agent warrants (217,391 shares) issued in the September 2026 Private Placement are excluded from the computation of diluted net loss per share because their effect would be antidilutive. The remaining 11,064,204 shares issuable upon exercise of other outstanding common stock warrants, including the Series A and Series B Warrants issued in the March 2026 Private Placement, are also excluded because their effect would be antidilutive. The 3,105,591 shares issuable under the September 2026 Pre-Funded Warrants are included in the computation of basic and diluted net loss per share from September 15, 2026.

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Operating expenses:
Research and development	$ 207	$ 570	$ 2,140	$ 12,067
General and administrative	2,616	3,027	11,473	10,431
Acquired in-process research and development			22,180
Loss from operations	(2,823)	(3,597)	(35,793)	(22,498)
Other income (expense), net:
Interest expense				(207)
Interest and other income, net		86	30	464
Financing costs related to equity line of credit	(806)		(806)
Total other income (expense), net	(806)	86	(776)	257
Net loss	$ (3,629)	$ (3,511)	$ (36,569)	$ (22,241)
Net loss per share of common stock, RSUs and pre-funded warrants, basic	$ (0.21)	$ (0.79)	$ (2.54)	$ (5.71)
Net loss per share of common stock, RSUs and pre-funded warrants, diluted	$ (0.21)	$ (0.79)	$ (2.54)	$ (5.71)
Weighted-average shares of common stock, RSUs and pre-funded warrants outstanding, basic	16,910,029	4,440,111	14,377,097	3,897,256
Weighted-average shares of common stock, RSUs and pre-funded warrants outstanding, diluted	16,910,029	4,440,111	14,377,097	3,897,256

Subsequent Events - (Details) $ / shares in Units, $ in Thousands, ¥ in Millions	Dec. 31, 2026 USD ($)	Nov. 30, 2026 USD ($)	Nov. 11, 2026 CNY (¥)	Nov. 09, 2026 shares	Oct. 27, 2026 USD ($)	Oct. 02, 2026 USD ($) $ / shares shares	Nov. 11, 2026 USD ($)	Nov. 04, 2026 USD ($)	Sep. 30, 2026 $ / shares shares	Jan. 20, 2026 $ / shares	Dec. 31, 2025 shares
Subsequent Event [Line Items]
Exercise price \| $ / shares									$ 0.805	$ 18.48
Issuance of common stock \| shares									16,889,767		4,927,161
Lincoln Park [Member]
Subsequent Event [Line Items]
Issuance of common stock \| shares									560,356
Vendor Settlement Agreement [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Outstanding balance payable	$ 100	$ 100
Subsequent Event [Member]
Subsequent Event [Line Items]
Unpaid rent								$ 200
Initial license fee \| ¥			¥ 3.0
Royalty on net sales percentage			6.00%
Issuance of common stock \| shares				3,195,881
Subsequent Event [Member] \| September 2026 Pre-Funded Warrants [Member]
Subsequent Event [Line Items]
Exercise price \| $ / shares						$ 0.001
Number of exercised warrant issued \| shares						3,105,591
Cash proceeds from exercise of warrants						$ 3
Issuance of common stock \| shares						3,105,591
Number of outstanding warrants \| shares
Subsequent Event [Member] \| Year One [Member]
Subsequent Event [Line Items]
Maintenance fees							$ 10,000
Subsequent Event [Member] \| Year Two [Member]
Subsequent Event [Line Items]
Maintenance fees							12,000
Subsequent Event [Member] \| Year Three [Member]
Subsequent Event [Line Items]
Maintenance fees							$ 14,000
Subsequent Event [Member] \| Lincoln Park [Member]
Subsequent Event [Line Items]
Shares issued in transaction \| shares				3,195,881
Subsequent Event [Member] \| Vendor Settlement Agreement [Member]
Subsequent Event [Line Items]
Outstanding balance					$ 700
Outstanding balance payable					200
Recognized gain					$ 500

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Schedule of Accrued Liabilities [Abstract]
Consulting, Accounting and Legal fees	$ 717	$ 447
Contract Research and Lab Equipment	154	7
Board Fees and Taxes	19	150
Accrued other liabilities	37	23
Accrued clinical trial liability	53	310
Total	$ 980	$ 937

Loan Payable

9 Months Ended

Sep. 30, 2026

Loan Payable [Abstract]

LOAN PAYABLE

6. LOAN PAYABLE

On April 8, 2025, the Company repaid in full all outstanding obligations under its Loan Agreement with Oxford Finance LLC (the “Lender” or “Oxford”), including accrued interest and applicable exit fees, using cash on hand. In connection with the repayment, the Company paid an aggregate of approximately $3.5 million, including an exit fee of approximately $0.6 million. The Loan Agreement was terminated in accordance with its terms, and all liens and security interests granted thereunder were released.

As of September 30, 2026 and December 31, 2025, the Company had no outstanding borrowings or other obligations under the Loan Agreement.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2026
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation—The unaudited interim Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been omitted. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2025. The Company has prepared the accompanying Condensed Consolidated Financial Statements on the same basis as the audited financial statements, and the unaudited interim condensed consolidated financial statements include, in the Company’s opinion, all adjustments, consisting only of normal recurring adjustments that the Company considers necessary for a fair presentation of its financial position and results of operations for these periods. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.
Use of Estimates	Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation, the valuation of warrants and other equity-linked instruments, and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.
Acquired In-Process Research and Development Expenses	Acquired In-Process Research and Development Expenses—Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used to determine the cost of the acquisition. Common stock issued as consideration in an acquisition of assets is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of the asset acquisition. Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in-process research and development, or IPR&D. Acquired IPR&D that has no alternative future use is expensed immediately as a component of in-process research and development expense in the condensed consolidated statements of operations. In addition to upfront consideration, acquisitions of assets may also include contingent consideration payments to be made for future milestone events or royalties on net sales of future products. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration payments in an acquisition of assets not required to be accounted for as a liability at fair value are recognized when the contingency is resolved and the consideration is paid or becomes payable. Contingent consideration payments made prior to regulatory approval are expensed as incurred.
Derivative Liability	Derivative Liability—The Company evaluates the terms of its financing agreements to identify embedded features that may require derivative accounting under ASC 815 – Derivatives and Hedging. Derivative instruments are recorded at fair value, with changes in fair value recognized in the condensed consolidated statement of operations. The Company determined that certain settlement provisions of the Lincoln Park Purchase Agreement (see Note 7) are not indexed to the Company’s own stock, and the Lincoln Park Purchase Agreement is therefore accounted for as a derivative liability in its entirety. The derivative liability is measured at fair value, which has been deemed de minimis as of September 30, 2026. Commitment shares issued to Lincoln Park and issuance costs related to the Lincoln Park Purchase Agreement are expensed as financing costs related to the equity line of credit when incurred
Recent Accounting Pronouncements	Recent Accounting Pronouncements—In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to improve disclosures about the types of expenses included in certain expense captions presented on the face of the income statement. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and related disclosures.

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(n))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 897	$ 7,707
Prepaid expenses and other current assets	712	562
Total current assets	1,609	8,269
Property and equipment — net	429	605
Operating lease right-of-use assets	6,642	7,540
Other noncurrent assets	81	517
Total assets	8,761	16,931
Current liabilities:
Accounts payable	2,031	1,038
Accrued expenses	980	937
Operating lease liabilities	1,336	1,192
Accrued compensation	322	147
Total current liabilities	4,669	3,314
Operating lease liabilities, less current portion	5,922	6,949
Total liabilities	10,591	10,263
Commitments and contingencies (Note 5)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 100,000,000 shares authorized; 16,889,767 and 4,927,161 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	17	5
Additional paid-in capital	277,098	240,031
Accumulated deficit	(278,945)	(233,368)
Total stockholders’ equity (deficit)	(1,830)	6,668
Total liabilities and stockholders’ equity (deficit)	$ 8,761	$ 16,931

Net Loss Per Share (Details) $ in Millions	9 Months Ended
Net Loss Per Share (Details) $ in Millions	Sep. 30, 2026 USD ($) shares
Net Loss Per Share [Line Items]
Purchase condition \| $	$ 25.0
Common Stock Warrants [Member]
Net Loss Per Share [Line Items]
Shares issued	6,211,182
Shares issuable upon exercise of common stock warrants	11,064,204
Placement Agent Warrants [Member]
Net Loss Per Share [Line Items]
Shares issued	217,391
September 2026 Pre-Funded Warrants [Member]
Net Loss Per Share [Line Items]
Shares issued	3,105,591
Lincoln Park [Member]
Net Loss Per Share [Line Items]
Purchase of contingently shares issued \| $	$ 25.0
Common Stock [Member] \| Lincoln Park [Member]
Net Loss Per Share [Line Items]
Shares issued	350,223

Segment Reporting

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

SEGMENT REPORTING

11. SEGMENT REPORTING

The Company operates and manages its business as one reportable and operating segment, which is the business of developing a pipeline of advanced CAR-T product candidates for immunology and oncology indications. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer. In February 2026, in connection with the Asset Acquisition, Matt Angel was appointed as President and Chief Executive Officer of the Company. Dr. Angel assumed the CODM duties upon his appointment, consistent with the historical performance by the prior CODM Stephen Brady. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.

As the Company has not generated revenue, the CODM assesses Company performance through the achievement of research goals towards advancing the Company’s product candidates through stages of development. As such, the CODM is regularly provided with budgeted and forecasted expense information as well as the Company’s Consolidated Financial Statements which is used to determine the Company’s liquidity needs and pipeline resource allocation.

The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company’s Condensed Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources. The consolidated net loss and significant segment expenses reviewed by the CODM are reported on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025. The measure of segment assets is reported on the Condensed Consolidated Balance Sheet as total assets. The CODM monitors the Company’s cash and cash equivalents as reported on the Condensed Consolidated Balance Sheets.

All financial information required for segment reporting that is provided to the chief operating decision maker is contained within the condensed consolidated financial statements and notes to condensed consolidated financial statements.

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

Erigen Assets Acquisition and Related Transactions (Tables)

9 Months Ended

Sep. 30, 2026

Erigen Assets Acquisition and Related Transactions [Abstract]

Schedule of Total Cost of Asset Acquisition

The total cost of the Asset Acquisition was calculated as follows (amounts in thousands, except share and per share amounts):

Shares issued to Erigen		8,268,495
Closing price of common stock on the acquisition date	$	2.41
Fair value of shares issued		19,927

Transaction costs		2,253
Total consideration	$	22,180

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) - Brisbane, California [Member] - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Commitments and Contingencies [Line Items]
2026 (excluding nine months ended September 30, 2026)	$ 482
2027	1,994
2028	2,064
2029	2,136
2030	2,210
Total minimum lease payments	8,886
Less: imputed interest	(1,628)
Present value of operating lease obligations	7,258	$ 8,141
Less: current portion	(1,336)
Noncurrent operating lease obligations	$ 5,922

Related Party Transactions

9 Months Ended

Sep. 30, 2026

RELATED PARTY TRANSACTIONS

13. RELATED PARTY TRANSACTIONS

Relationship with Factor Bioscience Inc.

Matt Angel, Ph.D., the Company’s President and Chief Executive Officer and a member of its Board of Directors, is also the majority owner, Chief Executive Officer, and chairman of Factor Bioscience LLC. Factor is a wholly-owned subsidiary of Factor Bioscience LLC. On February 3, 2026, the Company completed the Asset Purchase Agreement with Erigen and Factor, pursuant to which the Sellers agreed to sell and transfer to the Company all right, title, and interest in and to the Erigen Assets in exchange for an aggregate purchase price of 8,268,495 shares of our common stock, issued to Erigen on behalf of both Sellers. Erigen is a limited liability company and an affiliate of Factor. At the Erigen Closing, we issued 8,268,495 shares of our common stock to Erigen, resulting in Dr. Angel and Lotus Capital BVI Limited (“Lotus”) holding approximately 37% and 26% of our common stock, respectively, immediately following the Erigen Closing.

In November 2025, Erigen entered into an Amended and Restated License and Collaboration Agreement (the “Restated Factor License Agreement”) with Factor Bioscience Limited, which was assigned to the Company in connection with the Erigen Closing pursuant to the Asset Purchase Agreement. Pursuant to the Restated Factor License Agreement, we are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory. We are obligated to pay Factor Bioscience Limited, a wholly-owned subsidiary of Factor, up to $40 million in total upon achievement of certain development milestones for the programs and up to $620 million in total upon achievement of certain commercial milestones for the programs. In addition, we are required to pay Factor Bioscience Limited mid-single digit to high-teens royalties on net sales of licensed products on a country-by-country and licensed product-by-licensed product basis until expiration of the last to expire valid claim of certain licensed patents covering such licensed product in such country, subject to certain customary reductions, and low-to-mid double digit sublicense fees.

Further, in November 2025, Erigen entered into the Factor MSA, which was assigned to the Company in connection with the Erigen Closing pursuant to the Asset Purchase Agreement. In March 2026, the Board of Directors and Audit Committee of the Company approved and authorized the execution of the Work Order under the Factor MSA for R&D services beginning April 2026. Under this agreement, the Company committed to pay Factor for services through March 31, 2027, primarily related to the clinical advancement of TPST-2003, TPST-3003, and TPST-4003. In April 2026, the Company paid Factor a deposit of $0.4 million under the Work Order of the Factor MSA, recorded to prepaid expenses and other current assets, to be applied to the final invoice under the Work Order. In connection with the Letter Agreement, no portion of the deposit had been offset against Factor invoices as of September 30, 2026. As of September 30, 2026, the full deposit of $0.4 million is included in prepaid expenses and other current assets. Under the Letter Agreement, Factor agreed to return to the Company $0.2 million of the deposit previously made by the Company under the Work Order, for an interim period subject to certain conditions.

On May 12, 2026, the Company entered into the Letter Agreement with Factor relating to certain payment obligations of the Company under the Factor MSA and Work Order. Pursuant to the Letter Agreement, Factor agreed to permanently waive its right to receive the first $2.1 million payable by the Company to Factor under the Factor MSA and the Work Order. Because Factor is a related party of the Company and the waiver was provided by an entity controlled by a principal stockholder of the Company to furnish capital to the Company, the $2.1 million waiver has been accounted for as a capital contribution. Accordingly, $1.7 million of services rendered under the Work Order through June 30, 2026 were recorded to research and development expense and additional paid-in capital, with no amounts payable by the Company to Factor. No services were invoiced after June 30, 2026, so the remaining $0.4 million of the waiver has not been used. It will be recorded as research and development expense and additional paid-in capital as related services are performed. No gain or other income was recognized in connection with the waiver.

On September 22, 2026, the Company entered into the 2026 Factor MSA and 2026 Work Order (see Note 1), which the Audit Committee approved as a related party transaction, with Dr. Angel not participating. Under the 2026 Work Order, the Company pays Factor a fixed fee of $5.0 million per year in monthly installments of $416,667, plus third-party costs and a 10% project management fee, and either party may terminate on 30 days’ written notice. The 2026 Factor MSA and 2026 Work Order replace the Factor MSA and Work Order as a commercial matter. The Factor MSA and Work Order have not been terminated but are inactive, and no further services are requested or expected. The waiver under the Letter Agreement applies only to amounts payable under the Factor MSA and Work Order and does not apply to the 2026 Factor MSA or 2026 Work Order.

The Company recognized $0.1 million of research and development expense under the 2026 Work Order during the three months ended September 30, 2026, which is included in accrued expenses. Total research and development expense under the Factor arrangements was $0.1 million and $1.8 million for the three and nine months ended September 30, 2026, respectively. Other than the deposit and the $0.1 million accrued under the 2026 Work Order, no amounts were due to or from Factor as of September 30, 2026.

Further, pursuant to the Asset Purchase Agreement, Factor has made the Funding Commitment to provide the Company with financial support as further disclosed in Note 1 under “—Acquisition of Erigen Assets.” As of September 30, 2026, $8.9 million of availability remained under the Funding Commitment, with no amounts due to or from Factor related to the Funding Commitment in the accompanying condensed consolidated balance sheets.

The Company also entered into a private placement financing in March 2026, further disclosed in Note 1 under “Private Placements.” Pursuant to the Purchase Agreement, we sold an aggregate of 231,482 Shares, 231,482 Series A Warrants and 231,482 Series B Warrants to Factor in exchange for $0.5 million, before deducting placement agent fees and other offering expenses payable by us.

Legal Fee Settlement

Prior to the Erigen Closing, Erigen incurred approximately $0.4 million of legal fees with Wilson Sonsini Goodrich & Rosati (“WSGR”), which serves as intellectual property counsel to both the Company and Factor, in connection with due diligence and other matters predating the Asset Acquisition. These fees were not liabilities assumed by the Company under the Asset Purchase Agreement, and the Company had no contractual or legal obligation to pay them. In April 2026, WSGR redirected the outstanding invoices to the Company and requested payment. Because Erigen is affiliated with Factor, a related party of the Company, this matter was reviewed and approved by the Audit Committee of the Board of Directors as a related party transaction. In June 2026, the Company’s management agreed to settle the invoices on Erigen’s behalf in order to preserve the Company’s ongoing relationship with WSGR.

Because the obligation was not assumed under the Asset Purchase Agreement, was not required to complete the Erigen Closing, and resulted from a discretionary decision made after the Erigen Closing, the Company recognized the $0.4 million settlement as general and administrative expense during the nine months ended September 30, 2026. As of September 30, 2026, the settlement had not been paid and was included in accounts payable.

Advisory Agreement with Andrew Fang

In March 2026, the Board and Audit Committee of the Company approved and authorized the execution of an advisory agreement dated April 1, 2026 (the “Advisory Agreement”), with YQ Advisors Limited (“YQ”) pursuant to which YQ will provide various business development and corporate development activities to us at an hourly rate of (i) $1,250 for services provided by Andrew Fang and (ii) $250 for services provided by other YQ service providers, up to a maximum aggregate amount of $720,000 per year. The agreement has a term of 12 months, unless extended by mutual written agreement of the parties. Mr. Fang is the son of Bangxia Yang, the beneficial owner of Lotus, a greater than 5% holder of our common stock.

Services under the arrangement began April 2026. During the three and nine months ended September 30, 2026, the Company incurred $0.3 million and $0.4 million, respectively, in advisory fees as general and administrative expense under the Advisory Agreement. As of September 30, 2026, $0.1 million was in accounts payable and accrued liabilities.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

+ Details

Loan Payable (Details) - USD ($) $ in Thousands		9 Months Ended
Loan Payable (Details) - USD ($) $ in Thousands	Apr. 08, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Loan Payable [Abstract]
Repayment of loan	$ 3,500		$ 6,426
Debt instrument, exit fee	$ 600
Loans Payable

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended			9 Months Ended		12 Months Ended
	Jan. 27, 2026	Jan. 01, 2026	Jun. 15, 2023	Jun. 17, 2022	Sep. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025	Jun. 21, 2023
Stock-Based Compensation [Line Items]
Exercise price, percentage								110.00%
Vest over years								4 years
Date of grant years								10 years
Granted (in shares)								522,541	130,091
Fair value of stock options vested					$ 0		$ 100	$ 100	$ 1,600
Industry peers volatility rate					50.00%	25.00%
Weighted average volatility rate					50.00%	75.00%
Accelerated vesting of stock options										266,108
Share based compensation, modified stock options										416,005
Incremental compensation cost, recognized
Stock compensation expense						$ 100				$ 800
Voting power, percentage								10.00%
General and administrative [Member]
Stock-Based Compensation [Line Items]
Reversal of stock based compensation expense					$ 200			$ 200
2019 Employee Stock Purchase Plan [Member]
Stock-Based Compensation [Line Items]
Total number of shares, percentage				1.50%
Common stock reserved		38,461
Common stock, capital shares reserved for future issuance					107,069			107,069
Shares of common stock				38,461
Amended and Restated 2023 Equity Incentive Plan [Member]
Stock-Based Compensation [Line Items]
Total number of shares, percentage			4.00%
Common stock reserved, percentage			10 years
Common stock reserved	1,410,000	197,086
Common stock, capital shares reserved for future issuance					1,468,044			1,468,044
2023 Inducement Plan [Member]
Stock-Based Compensation [Line Items]
Common stock, capital shares reserved for future issuance					67,615			67,615
Individuals who were not Previously Employees or Directors of Company [Member] \| 2023 Inducement Plan [Member]
Stock-Based Compensation [Line Items]
Common stock, capital shares reserved for future issuance											88,461
Share-based Payment Arrangement, Employee [Member]
Stock-Based Compensation [Line Items]
Granted (in shares)								522,541	130,091
Unvested employee stock options					$ 585		$ 450	$ 585	$ 450
Weighted-average period								3 years 1 month 6 days	1 year 8 months 12 days
Weighted-average grant date fair value								$ 1.81	$ 11.2

Stock-Based Compensation - Schedule of Summary of Stock Options (Details) - $ / shares	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Stock-Based Compensation [Abstract]
Outstanding at beginning (in shares)	450,104	320,013
Granted (in shares)	522,541	130,091
Exercised (in shares)
Cancelled and forfeited (in shares)	(405,879)
Outstanding at end (in shares)	566,766
Outstanding at beginning (in dollars per share)	$ 64.44	$ 86.06
Granted (in dollars per share)	2.03	11.2
Exercised (in dollars per share)
Cancelled and forfeited (in dollars per share)	40.17
Outstanding at end (in dollars per share)	$ 23.91

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Retirement Plan

9 Months Ended

Sep. 30, 2026

Retirement Plan [Abstract]

RETIREMENT PLAN

9. RETIREMENT PLAN

The Company participates in a qualified 401(k) Plan sponsored by its professional service organization. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. During the three and nine months ended September 30, 2026, the Company contributed $12 and $44 to the 401(k) Plan, respectively. During the three and nine months ended September 30, 2025, the Company contributed $5 and $120 to the 401(k) Plan, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

Balance Sheet Components - Schedule of Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Schedule of Summary of Property and Equipment, Net [Line Items]
Property and equipment	$ 2,058	$ 2,058
Less accumulated depreciation	(1,629)	(1,453)
Property and equipment-net	429	605
Computer equipment and software [Member]
Schedule of Summary of Property and Equipment, Net [Line Items]
Property and equipment	151	151
Furniture and fixtures [Member]
Schedule of Summary of Property and Equipment, Net [Line Items]
Property and equipment	263	263
Lab equipment [Member]
Schedule of Summary of Property and Equipment, Net [Line Items]
Property and equipment	1,446	1,446
Leasehold improvements [Member]
Schedule of Summary of Property and Equipment, Net [Line Items]
Property and equipment	$ 198	$ 198

- Definition

Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 905
-SubTopic 360
-Name Accounting Standards Codification
-Section 25
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478704/905-360-25-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482222/360-10-30-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

+ Details

- Definition

Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478443/942-360-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings	18,059,543	450,568
Options to purchase common stock [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings	566,766	450,104
Common Stock Warrants [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings	17,492,777	464

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2026

Fair Value Measurements [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables present the Company’s fair value hierarchy for assets measured at fair value on a recurring basis:

	As of September 30, 2026
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	897	$	—	$	—	$	897
Total	$	897	$	—	$	—	$	897

	As of December 31, 2025
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	7,707	$	—	$	—	$	7,707
Total	$	7,707	$	—	$	—	$	7,707

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	$ 897	$ 7,707
Total	897	7,707
Level 1 [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	897	7,707
Total	897	7,707
Level 2 [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents
Total
Level 3 [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents
Total

Commitments and Contingencies (Details) $ in Thousands, ¥ in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2026 CNY (¥) Rate	Jul. 30, 2026 USD ($)	Jan. 31, 2022 ft²	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Aug. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)
Commitments and Contingencies [Line Items]
Operating lease right-of-use assets				$ 6,642		$ 6,642			$ 7,540
Restricted Cash
Letter of Credit [Member]
Commitments and Contingencies [Line Items]
Deposit amount				388		388		$ 388
Brisbane, California [Member]
Commitments and Contingencies [Line Items]
Term of contract			8 years
Area of property (in sqft) \| ft²			20,116
Operating lease commencement month and year			2022-12
Operating lease right-of-use assets				6,642		6,642			7,540
Present value of operating lease obligations				7,258		7,258			$ 8,141
Rent expense				491	$ 486	1,459	$ 1,459
SOW [Member] \| Maximum [Member]
Commitments and Contingencies [Line Items]
Development fee		$ 2,000
SOW [Member] \| Minimum [Member]
Commitments and Contingencies [Line Items]
Development fee		$ 1,500
License Agreement [Member]
Commitments and Contingencies [Line Items]
License fee \| ¥	¥ 3.0
Royalty [Member] \| License Agreement [Member]
Commitments and Contingencies [Line Items]
Net sale percentage \| Rate	6.00%
Year One [Member] \| License Agreement [Member]
Commitments and Contingencies [Line Items]
Maintenance fees				10,000		10,000
Year Two [Member] \| License Agreement [Member]
Commitments and Contingencies [Line Items]
Maintenance fees				12,000		12,000
Year Three [Member] \| License Agreement [Member]
Commitments and Contingencies [Line Items]
Maintenance fees				$ 14,000		$ 14,000

Retirement Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Retirement Plan (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Retirement Plan [Abstract]
Contributed amount	$ 12	$ 5	$ 44	$ 120

Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Schedule of Stock Based Compensation Expense [Line Items]
Stock-based compensation expense	$ (54)	$ 61	$ 163	$ 2,542
Research and development [Member]
Schedule of Stock Based Compensation Expense [Line Items]
Stock-based compensation expense	3	9	8	979
General and administrative [Member]
Schedule of Stock Based Compensation Expense [Line Items]
Stock-based compensation expense	$ 51	$ 52	$ 155	$ 1,563